Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de cardiologie
Language :
English
Title :
2018 ESC/EACTS Guidelines on myocardial revascularization.
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, ESC Committee for Practice Guidelines, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949-3003.
Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA 2012;308:1237-1245.
Norgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, et al. Group NXTTS. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: The NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). J Am Coll Cardiol 2014; 63:1145-1155.
Douglas PS, Pontone G, Hlatky MA, Patel MR, Norgaard BL, Byrne RA, et al. PLATFORM Investigators. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs usual care in patients with suspected coronary artery disease: The prospective longitudinal trial of FFR(CT): Outcome and resource impacts study. Eur Heart J 2015;36:3359-3367.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomizedcontrolled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-2012.
Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. International Society for Heart Lung Transplantation Infectious Diseases Council, International Society for Heart Lung Transplantation Pediatric Transplantation Council, International Society for Heart Lung Transplantation Heart Failure, Transplantation Council. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 2016; 35:1-23.
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant 2013;32:157-187.
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617-1625.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002;39:1151-1158.
Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: Inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013;6: 363-372.
Ahn JM, Park DW, Shin ES, Koo BK, Nam CW, Doh JH, et al. IRIS-FFR Investigators. Fractional flow reserve and cardiac events in coronary artery disease: Data from a prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve). Circulation 2017;135:2241-2251.
Bech GJ, De Bruyne B, Bonnier HJ, Bartunek J, Wijns W, Peels K, et al. Long-term follow-up after deferral of percutaneous transluminal coronary angioplasty of intermediate stenosis on the basis of coronary pressure measurement. J Am Coll Cardiol 1998;31:841-847.
Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: A randomized trial. Circulation 2001;103:2928-2934.
Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007;49:2105-2111.
Adjedj J, De Bruyne B, Flore V, Di Gioia G, Ferrara A, Pellicano M, et al. Significance of intermediate values of fractional flow reserve in patients with coronary artery disease. Circulation 2016;133:502-508.
Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 2017;376:1824-1834.
Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, et al. iFR-SWEDEHEART Investigators. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 2017;376:1813-1823.
Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, et al. Investigators of the Registre Francais de la FFR-R3F. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: Insights from a large French multicenter fractional flow reserve registry. Circulation 2014;129: 173-185.
Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, et al. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain the RIPCORD study. Circ Cardiovasc Interv 2014;7:248-255.
Baptista SB, Raposo L, Santos L, Ramos R, Cale R, Jorge E, et al. Impact of routine fractional flow reserve evaluation during coronary angiography on management strategy and clinical outcome: One-year results of the POST-IT. Circ Cardiovasc Interv 2016;9:e003288-000.
Van Belle E, Baptista SB, Raposo L, Henderson J, Rioufol G, Santos L, et al. PRIMER-FFR Study Group. Impact of Routine Fractional Flow Reserve on Management Decision and 1-Year Clinical Outcome of Patients With Acute Coronary Syndromes: PRIME-FFR (Insights From the POST-IT [Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary Disease] and R3F [French FFR Registry] Integrated Multicenter Registries-Implementation of FFR [Fractional Flow Reserve] in Routine Practice). Circ Cardiovasc Interv 2017;10:e004296.
Van Belle E, Dupouy P, Rioufol G. Routine fractional flow reserve combined to diagnostic coronary angiography as a one-stop procedure: Episode 3. Circ Cardiovasc Interv 2016;9:e004137.
Johnson NP, Toth GG, Lai D, Zhu H, Acar G, Agostoni P, et al. Prognostic value of fractional flow reserve: Linking physiologic severity to clinical outcomes. J Am Coll Cardiol 2014;64:1641-1654.
Mallidi J, Atreya AR, Cook J, Garb J, Jeremias A, Klein LW, et al. Longterm outcomes following fractional flow reserve-guided treatment of angiographically ambiguous left main coronary artery disease: A metaanalysis of prospective cohort studies. Catheter Cardiovasc Interv 2015; 86:12-18.
Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis G, Sarno G, et al. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 2009;120:1505-1512.
Yong AS, Daniels D, De Bruyne B, Kim HS, Ikeno F, Lyons J, et al. Fractional flow reserve assessment of left main stenosis in the presence of downstream coronary stenoses. Circ Cardiovasc Interv 2013;6: 161-165.
Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, et al. Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. Circulation 2013;128:1405-1411.
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-224.
Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, et al. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol 2010;56:177-184.
van Nunen LX, Zimmermann FM, Tonino PA, Barbato E, Baumbach A, Engstrom T, et al. FAME study Investigators. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet 2015;386:1853-1860.
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367: 991-1001.
Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, Barbato E, Tonino P, et al. FAME 2 Trial Investigators. Clinical outcomes and costeffectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: Three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation 2018;137:480-487.
Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J 2017;38:3124-3134.
Waksman R, Legutko J, Singh J, Orlando Q, Marso S, Schloss T, et al. FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. J Am Coll Cardiol 2013;61:917-923.
Park SJ, Kim YH, Park DW, Lee SW, Kim WJ, Suh J, et al. MAINCOMPARE Investigators. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Interv 2009;2:167-177.
Fassa AA, Wagatsuma K, Higano ST, Mathew V, Barsness GW, Lennon RJ, et al. Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: A long-term follow-up study. J Am Coll Cardiol 2005;45:204-211.
de la Torre Hernandez JM, Hernandez Hernandez F, Alfonso F, Rumoroso JR, Lopez-Palop R, Sadaba M, et al. LITRO Study Group. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. J Am Coll Cardiol 2011;58:351-358.
Park SJ, Ahn JM, Kang SJ, Yoon SH, Koo BK, Lee JY, et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis. JACC Cardiovasc Interv 2014;7: 868-874.
Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334: 1703-1708.
Ayton DR, Barker AL, Peeters G, Berkovic DE, Lefkovits J, Brennan A, et al. Exploring patient-reported outcomes following percutaneous coronary intervention: A qualitative study. Health Expect 2018;21:457-465.
Myles PS. Meaningful outcome measures in cardiac surgery. J Extra Corpor Technol 2014;46:23-27.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. Scientific Document ESC Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.
Head SJ, Kaul S, Mack MJ, Serruys PW, Taggart DP, Holmes DR Jr, et al. The rationale for Heart Team decision-making for patients with stablecomplex coronary artery disease. Eur Heart J 2013;34:2510-2518.
Filardo G, Maggioni AP, Mura G, Valagussa F, Valagussa L, Schweiger C, et al. The consequences of under-use of coronary revascularization; Results of a cohort study in Northern Italy. Eur Heart J 2001;22:654-662.
Yates MT, Soppa GK, Valencia O, Jones S, Firoozi S, Jahangiri M. Impact of European Society of Cardiology and European Association for Cardiothoracic Surgery Guidelines on Myocardial Revascularization on the activity of percutaneous coronary intervention and coronary artery bypass graft surgery for stable coronary artery disease. J Thorac Cardiovasc Surg 2014;147:606-610.
Organisation for Economic Co-operation and Development. Health at a glance. http://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm accessed July 21, 2018.
Bradley SM, Bohn CM, Malenka DJ, Graham MM, Bryson CL, McCabe JM, et al. Temporal trends in percutaneous coronary intervention appropriateness: Insights from the clinical outcomes assessment program. Circulation 2015;132:20-26.
Hannan EL, Samadashvili Z, Cozzens K, Gesten F, Osinaga A, Fish DG, et al. Changes in percutaneous coronary interventions deemed "inappropriate" by appropriate use criteria. J Am Coll Cardiol 2017;69: 1234-1242.
Denvir MA, Pell JP, Lee AJ, Rysdale J, Prescott RJ, Eteiba H, et al. Variations in clinical decision-making between cardiologists and cardiac surgeons; A case for management by multidisciplinary teams J Cardiothorac Surg 2006;1:2.
Pavlidis AN, Perera D, Karamasis GV, Bapat V, Young C, Clapp BR, et al. Implementation and consistency of Heart Team decision-making in complex coronary revascularisation. Int J Cardiol 2016;206:37-41.
Sanchez CE, Dota A, Badhwar V, Kliner D, Smith AJ, Chu D, et al. Revascularization heart team recommendations as an adjunct to appropriate use criteria for coronary revascularization in patients with complex coronary artery disease. Catheter Cardiovasc Interv 2016;88: E103-E112.
Sobolev BG, Fradet G, Kuramoto L, Rogula B. The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: A population-based observational study. J Cardiothorac Surg 2013;8:74.
Head SJ, da Costa BR, Beumer B, Stefanini GG, Alfonso F, Clemmensen PM, et al. Adverse events while awaiting myocardial revascularization: A systematic review and meta-analysis. Eur J Cardiothorac Surg 2017;52: 206-217.
Graham MM, Knudtson ML, O'Neill BJ, Ross DB, Canadian Cardiovascular Society Access to Care Working Group. Treating the right patient at the right time: Access to cardiac catheterization, percutaneous coronary intervention and cardiac surgery. Can J Cardiol 2006;22: 679-683.
Truffa MA, Alves GM, Bernardi F, Esteves Filho A, Ribeiro E, Galon MZ, et al. Does ad hoc coronary intervention reduce radiation exposure-Analysis of 568 patients. Arq Bras Cardiol 2015;105:487-492.
Hannan EL, Samadashvili Z, Walford G, Holmes DR, Jacobs A, Sharma S, et al. Predictors and outcomes of ad hoc versus non-ad hoc percutaneous coronary interventions. JACC Cardiovasc Interv 2009;2:350-356.
RITA-2 Trial Participants Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461-468.
TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): A randomised trial. Lancet 2001;358:951-957.
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356: 1503-1516.
Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSI II randomized controlled trial. JAMA 2007;297:1985-1991.
BARI Study Group 2D, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360: 2503-2515.
Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, et al. Tenyear follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122: 949-957.
Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. ORBITA Investigators. Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial. Lancet 2018;391:31-40.
Chaitman BR, Mori Brooks M, Fox K, Luscher TF. ORBITA revisited: What it really means and what it does not Eur Heart J 2018;39:963-965.
Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-Yehuda O, et al. Quality-of-life after everolimus-eluting stents or bypass surgery for left-main disease: Results from the EXCEL trial. J Am Coll Cardiol 2017;70:3113-3122.
Abdallah MS, Wang K, Magnuson EA, Osnabrugge RL, Kappetein AP, Morice MC, et al. Quality of life after surgery or DES in patients with 3-vessel or left main disease. J Am Coll Cardiol 2017;69:2039-2050.
Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, et al. FREEDOM Trial Investigators. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: A randomized clinical trial. JAMA 2013;310:1581-1590.
Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563-570.
Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 2013;127:2177-2185.
Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, et al. Alberta for Provincial Project in Outcome Assessment Coronary Heart Disease Investigators. Long-term survival in 11, 661 patients with multivessel coronary artery disease in the era of stenting: A report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J 2001;142: 119-126.
Lee PH, Ahn JM, Chang M, Baek S, Yoon SH, Kang SJ, et al. Left main coronary artery disease: Secular trends in patient characteristicstreatments, and outcomes. J Am Coll Cardiol 2016;68:1233-1246.
Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006;82:1420-1428; discussion 1428-1429.
Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008;358:331-341.
Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation 2012;125:1870-1879.
Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995;91:2335-2344.
Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009;120:2529-2540.
Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985;312:1665-1671.
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-1616.
Jones RH, Kesler K, Phillips HR III, Mark DB, Smith PK, Nelson CL, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996;111:1013-1025.
Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528-1534.
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511-1520.
Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, Favaloro RR, et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol 2014;64:553-561.
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al. STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: An analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016;134:1314-1324.
Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011;32:1012-1024.
Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997;95:2037-2043.
Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117:1283-1291.
Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107: 2900-2907.
Gada H, Kirtane AJ, Kereiakes DJ, Bangalore S, Moses JW, Genereux P, et al. Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia. Am J Cardiol 2015;115:1194-1199.
Stergiopoulos K, Boden WE, Hartigan P, Mobius-Winkler S, Hambrecht R, Hueb W, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med 2014;174:232-240.
Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, et al. Japanese Stable Angina Pectoris Study Investigators. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: A randomized, comparative, multicenter study. JACC Cardiovasc Interv 2008;1:469-479.
Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis. Circulation 2005;111:2906-2912.
Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A metaanalysis of 17 randomized trials of a percutaneous coronary interventionbased strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:894-904.
Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: A quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-918.
Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 2013;127:769-781.
Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: A systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012;5:476-490.
Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013;29:472-482.
De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al. FAME-2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 2014;371:1208-1217.
Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: Meta-analysis of randomised controlled trials. BMJ 2000;321:73-77.
Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: Meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:312-319.
Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: Network meta-analysis. BMJ 2014;348: G3859.
Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009;122:152-161.
Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961-972.
Boudriot E, Thiele H, Walther T, Liebetrau C, Boeckstegers P, Pohl T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 2011;57: 538-545.
Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011;364:1718-1727.
Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015;372:1204-1212.
Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): A prospective, randomised, open-label, non-inferiority trial. Lancet 2016;388: 2743-2752.
Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, et al. EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016;375: 2223-2235.
Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734-744; discussion 744-745.
Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: Part 1-coronary artery bypass grafting surgery. Ann Thorac Surg 2009;88: S2-S22.
Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: Part 3-valve plus coronary artery bypass grafting surgery. Ann Thorac Surg 2009;88:S43-S62.
Biancari F, Vasques F, Mikkola R, Martin M, Lahtinen J, Heikkinen J. Validation of EuroSCORE II in patients undergoing coronary artery bypass surgery. Ann Thorac Surg 2012;93:1930-1935.
Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, et al. Performance of EuroSCORE II in a large US database: Implications for transcatheter aortic valve implantation. Eur J Cardiothorac Surg 2014;46:400-408.
Sullivan PG, Wallach JD, Ioannidis JP. Meta-analysis comparing established risk prediction models (EuroSCORE II, STS Score, and ACEF Score) for perioperative mortality during cardiac surgery. Am J Cardiol 2016; 118:1574-1582.
Kirmani BH, Mazhar K, Fabri BM, Pullan DM. Comparison of the EuroSCORE II and Society of Thoracic Surgeons 2008 risk tools. Eur J Cardiothorac Surg 2013;44:999-1005.
Velicki L, Cemerlic-Adjic N, Pavlovic K, Mihajlovic BB, Bankovic D, Mihajlovic B, et al. Clinical performance of the EuroSCORE II compared with the previous EuroSCORE iterations. Thorac Cardiovasc Surg 2014; 62:288-297.
Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219-227.
Wykrzykowska JJ, Garg S, Girasis C, de Vries T, Morel MA, van Es GA, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol 2010; 56:272-277.
Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, et al. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- A nd everolimus-eluting stents: A substudy of the RESOLUTE All Comers Trial. JACC Cardiovasc Interv 2011;4:432-441.
Zhao M, Stampf S, Valina C, Kienzle RP, Ferenc M, Gick M, et al. Role of euroSCORE II in predicting long-term outcome after percutaneous catheter intervention for coronary triple vessel disease or left main stenosis. Int J Cardiol 2013;168:3273-3279.
Cavalcante R, Sotomi Y, Mancone M, Whan Lee C, Ahn JM, Onuma Y, et al. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: A pooled analysis of patient level data from the SYNTAXPRECOMBAT, and BEST trials. Eur Heart J 2017;38: 1969-1977.
Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-638.
Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation 2014;129: 2388-2394.
Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, et al. Coronary artery bypass grafting vs percutaneous coronary intervention for patients with three-vessel disease: Final five-year follow-up of the SYNTAX trial. Eur Heart J 2014;35:2821-2830.
Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: A pooled analysis of individual patient data. Lancet 2018;391:939-948.
Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD, et al. Prognostic value of site SYNTAX score and rationale for combining anatomic and clinical factors in decision making: Insights from the SYNTAX trial. J Am Coll Cardiol 2014;64:423-432.
Medina A, Suarez de Lezo J, Pan M. [A new classification of coronary bifurcation lesions].Rev Esp Cardiol 2006; 59: 183.
Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: Development and validation of SYNTAX score II. Lancet 2013;381:639-650.
Campos CM, Garcia-Garcia HM, van Klaveren D, Ishibashi Y, Cho YK, Valgimigli M, et al. Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. Int J Cardiol 2015;187:111-115.
Sotomi Y, Cavalcante R, van Klaveren D, Ahn JM, Lee CW, de Winter RJ, et al. Individual long-term mortality prediction following either coronary stenting or bypass surgery in patients with multivessel and/or unprotected left main disease: An external validation of the SYNTAX Score II model in the 1480patients of the BEST and PRECOMBAT randomized controlled trials. JACC Cardiovasc Interv 2016;9:1564-1572.
Campos CM, van Klaveren D, Farooq V, Simonton CA, Kappetein AP, Sabik JF III, et al. Investigators ET. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: Prospective validation of the SYNTAX Score II. Eur Heart J 2015;36:1231-1241.
Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas CV, Holmes DR, et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: The SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. J Am Coll Cardiol 2013;61:282-294.
Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D, et al. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: A meta-analysis of 89883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol 2013;62:1421-1431.
Zimarino M, Ricci F, Romanello M, Di Nicola M, Corazzini A, De Caterina R. Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. Catheter Cardiovasc Interv 2016; 87:3-12.
Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013;128:141-151.
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 2015;372:1213-1222.
Ahn JM, Park DW, Lee CW, Chang M, Cavalcante R, Sotomi Y, et al. Comparison of stenting versus bypass surgery according to the completeness of revascularization in severe coronary artery disease: Patient-level pooled analysis of the SYNTAX, PRECOMBAT, and BEST Trials. JACC Cardiovasc Interv 2017;10:1415-1424.
Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. FAMOUS-NSTEMI Investigators. Fractional flow reserve vs angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: The British Heart Foundation FAMOUSNSTEMI randomized trial. Eur Heart J 2015;36:100-111.
Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of EuroSCORE II, original EuroSCORE, and The Society of Thoracic Surgeons Risk Score in cardiac surgery patients. Ann Thorac Surg 2016;102:573-579.
Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007;334:617.
Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 2008;1: 483-491.
Blazek S, Holzhey D, Jungert C, Borger MA, Fuernau G, Desch S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC Cardiovasc Interv 2013;6: 20-26.
Hannan EL, Zhong Y, Walford G, Holmes DR Jr, Venditti FJ, Berger PB, et al. Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol 2014;64:2717-2126.
Blazek S, Rossbach C, Borger MA, Fuernau G, Desch S, Eitel I, et al. Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial. JACC Cardiovasc Interv 2015;8: 30-38.
Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009;53:2324-2331.
Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: A meta-analysis of randomized clinical data. J Am Coll Cardiol 2011;58:1426-1432.
Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-Year outcomes of the PRECOMBAT study. J Am Coll Cardiol 2015;65: 2198-2206.
Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farooq V, Tateishi H, et al. Outcomes after percutaneous coronary intervention or bypass surgery in patients with unprotected left main disease. J Am Coll Cardiol 2016; 68:999-1009.
Giacoppo D, Colleran R, Cassese S, Frangieh AH, Wiebe J, Joner M, et al. Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: A systematic review and meta-analysis. JAMA Cardiol 2017;2:1079-1088.
Chang M, Ahn JM, Lee CW, Cavalcante R, Sotomi Y, Onuma Y, et al. Long-term mortality after coronary revascularization in nondiabetic patients with multivessel disease. J Am Coll Cardiol 2016;68:29-36.
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:2375-2384.
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus eluting stents versus coronary artery bypass graft surgery for patients with diabetes mellitus and multivessel disease. Circ Cardiovasc Interv 2015;8:e002626.
Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: Comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc 2013;2:e000354.
Herbison P, Wong CK. Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years A systematic review and meta-regression. BMJ Open 2015;5:e010055.
Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, et al. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol 2013;61: 808-816.
Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, et al. Investigators S. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013;43:1006-1013.
Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010;55:432-440.
Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, et al. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: Patient-level pooled analysis of 6081 patients. Circ Cardiovasc Interv 2016;9:e003255.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. Scientific Document ESC Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent STSegment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-922.
Shishehbor MH, Venkatachalam S, Sun Z, Rajeswaran J, Kapadia SR, Bajzer C, et al. A direct comparison of early and late outcomes with three approaches to carotidã revascularization and open heart surgery. J Am Coll Cardiol 2013;62:1948-1956.
Cheruvu PK, Finn AV, Gardner C, Caplan J, Goldstein J, Stone GW, et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: A pathologic study. J Am Coll Cardiol 2007;50:940-949.
Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ, Veterans Affairs Non-Q-Wave Infarction Strategies in-Hospital (VANQWISH) Trial Investigators. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002;39:1456-1463.
Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365:1980-1989.
Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et al. TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360:2165-2175.
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. ACCOAST Investigators. Pretreatment with prasugrel in non-STsegment elevation acute coronary syndromes. N Engl J Med 2013;369: 999-1010.
Thiele H, Rach J, Klein N, Pfeiffer D, Hartmann A, Hambrecht R, et al. Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: The Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). Eur Heart J 2012;33:2035-2043.
Tanaka A, Shimada K, Tearney GJ, Kitabata H, Taguchi H, Fukuda S, et al. Conformational change in coronary artery structure assessed by optical coherence tomography in patients with vasospastic angina. J Am Coll Cardiol 2011;58:1608-1613.
Kato M, Dote K, Sasaki S, Kagawa E, Nakano Y, Watanabe Y, et al. Presentations of acute coronary syndrome related to coronary lesion morphologies as assessed by intravascular ultrasound and optical coherence tomography. Int J Cardiol 2013;165:506-511.
Motreff P, Malcles G, Combaret N, Barber-Chamoux N, Bouajila S, Pereira B, et al. How and when to suspect spontaneous coronary artery dissection: Novel insights from a single-centre series on prevalence and angiographic appearance. EuroIntervention 2017;12: E2236-e2243.
Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006;48:1319-1325.
Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010;55: 2435-2445.
Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, et al. MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomised multicentre trial. Lancet 2015;385:2465-2476.
Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015; 373:2038-2047.
Katritsis DG, Siontis GC, Kastrati A, van't Hof AW, Neumann FJ, Siontis KC, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J 2011;32:32-40.
Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: A systematic review and metaanalysis. Ann Intern Med 2013;158:261-270.
Jobs A, Mehta SR, Montalescot G, Vicaut E, Van't Hof AWJ, Badings EA, et al. Optimal timing of an invasive strategy in patients with non-STelevation acute coronary syndrome: A meta-analysis of randomised trials. Lancet 2017;390:737-746.
Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, et al. COMFORTABLE AMI Trial Investigators. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA 2012;308: 777-787.
Sabate M, Raber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: A pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv 2014;7:55-63.
Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, et al. PRODIGY Investigators. Two-year outcomes after first-or secondgeneration drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: A prespecified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC Cardiovasc Interv 2014;7:20-28.
Thiele H, de Waha S, Zeymer U, Desch S, Scheller B, Lauer B, et al. Effect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: The TATORT-NSTEMI trial. J Am Coll Cardiol 2014;64: 1117-1124.
Hakeem A, Edupuganti MM, Almomani A, Pothineni NV, Payne J, Abualsuod AM, et al. Long-term prognosis of deferred acute coronary syndrome lesions based on nonischemic fractional flow reserve. J Am Coll Cardiol 2016;68:1181-1191.
Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;3:9-16.
Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
Genereux P, Palmerini T, Caixeta A, Cristea E, Mehran R, Sanchez R, et al. SYNTAX score reproducibility and variability between interventional cardiologistscore laboratory technicians, and quantitative coronary measurements. Circ Cardiovasc Interv 2011;4:553-561.
Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged compared with multi-staged PCI in multivessel NSTEMI patients: The SMILE Trial. J Am Coll Cardiol 2016;67: 264-272.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al. TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33.
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, et al. Ticagrelor vs clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: Results from the PLATO trial. Eur Heart J 2014;35:2083-2093.
Curtis JP, Schreiner G, Wang Y, Chen J, Spertus JA, Rumsfeld JS, et al. Allcause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol 2009;54:903-907.
Meadows ES, Bae JP, Zagar A, Sugihara T, Ramaswamy K, McCracken R, et al. Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: A retrospective analysis. BMC Res Notes 2012;5:342.
Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. CULPRIT-SHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017;377: 2419-2432.
Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011;108:617-624.
Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013;145: 1577-1583.
Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C, et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: A prospective observational study. Br J Anaesth 2016;117:309-315.
Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, et al. Comparison of outcome of coronary artery bypass grafting versus drugeluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol 2017;120:380-386.
Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. J Am Coll Cardiol 2011;57:2389-2397.
Ramanathan K, Abel JG, Park JE, Fung A, Mathew V, Taylor CM, et al. Surgical versus percutaneous coronary revascularization in patients with diabetes and acute coronary syndromes. J Am Coll Cardiol 2017;70: 2995-3006.
Kolte D, Khera S, Dabhadkar KC, Agarwal S, Aronow WS, Timmermans R, et al. Trends in coronary angiography revascularization, and outcomes of cardiogenic shock complicating non-ST-elevation myocardial infarction. Am J Cardiol 2016;117:1-9.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39: 119-177.
Scholz KH, Maier SKG, Maier LS, Lengenfelder B, Jacobshagen C, Jung J, et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: Results from the German prospective multicentre FITT-STEMI trial. Eur Heart J 2018;39:1065-1074.
Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: Quantitative review of randomised trials. Lancet 2006;367: 579-588.
Boersma E, Primary Coronary Angioplasty vs Thrombolysis Group. Does time matter A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779-788.
Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000;283:2686-2692.
Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: A randomised study. Lancet 2002;360:825-829.
Bonnefoy E, Steg PG, Boutitie F, Dubien PY, Lapostolle F, Roncalli J, CAPTIM Investigators, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: A 5-year follow-up. Eur Heart J 2009;30:1598-1606.
Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, et al. National Registry of Investigators Myocardial Infarction. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 2011; 124:2512-2251.
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in STsegment elevation myocardial infarction. N Engl J Med 2013;368: 1379-1387.
Park DW, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA 2014;312:2019-2027.
Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, et al. HORIZONS-AMI Trial Investigators. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: Analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2011;58:704-711.
Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in STelevation myocardial infarction: Major adverse cardiac events during long-term follow-up. Heart 2010;96:662-667.
Di Mario, C Mara, S Flavio, A Imad, S Antonio, M Anna, P et al. Single vs multivessel treatment during primary angioplasty: Results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent 2004;6:128-133.
Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;369:1115-1123.
Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: The CvLPRIT trial. J Am Coll Cardiol 2015;65:963-972.
Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, et al. DANAMI-PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): An open-label, randomised controlled trial. Lancet 2015; 386:665-671.
Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Compare-Acute Investigators. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017;376:1234-1244.
Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: A pairwise and network meta-analysis of randomized trials. JACC Cardiovasc Interv 2017;10:315-324.
Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-2713.
Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380: 1482-1490.
Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Jimenez-Quevedo P, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus baremetal stents (EXAMINATION): 5-year results of a randomised trial. Lancet 2016;387:357-366.
Belle L, Motreff P, Mangin L, Range G, Marcaggi X, Marie A, et al. MIMI Investigators. Comparison of immediate with delayed stenting using the Minimalist Immediate Mechanical Intervention approach in acute STsegment-elevation myocardial infarction: The MIMI study. Circ Cardiovasc Interv 2016;9:e003388.
Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no-or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol 2014;63:2088-2098.
Kelbaek H, Hofsten DE, Kober L, Helqvist S, Klovgaard L, Holmvang L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): An open-label, randomised controlled trial. Lancet 2016;387:2199-2206.
De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 2013;166: 606-612.
Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. TASTE Trial Investigators. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013;369: 1587-1597.
Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014;371:1111-1120.
Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015;372(15):1389-1398.
Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, et al. TOTAL Investigators. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet 2016;387:127-135.
Jolly SS, Cairns JA, Yusuf S, Meeks B, Gao P, Hart RG, et al. TOTAL Investigators. Stroke in the TOTAL trial: A randomized trial of routine thrombectomy vs percutaneous coronary intervention alone in ST elevation myocardial infarction. Eur Heart J 2015;36:2364-2372.
Jolly SS, James S, Dzavik V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: An individual patient meta-analysis: Thrombectomy Trialists Collaboration. Circulation 2017;135(2):143-152.
Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010;55:102-110.
Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. TRANSFER-AMI Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009;360:2705-2718.
Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. CARES-in-AMI Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): An open prospective, randomised, multicentre trial. Lancet 2008;371:559-568.
Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. REACT Trial Investigators. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353:2758-2768.
Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. Beyond 12 hours Reperfusion AlternatiVe Evaluation Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial. JAMA 2005;293:2865-2872.
Busk M, Kaltoft A, Nielsen SS, Bottcher M, Rehling M, Thuesen L, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for 12 h vs 12-72 h.Eur Heart J 2009;30: 1322-1330
Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355: 2395-2407.
Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996;348:771-775.
Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-742.
Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: A meta-analysis. Circulation 2003;108:1809-1814.
Mehilli J, Kastrati A, Schulz S, Frungel S, Nekolla SG, Moshage W, et al. Bavarian Reperfusion Alternatives Evaluation-Study 3 I. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation 2009;119: 1933-1940.
Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, et al. Implementation of guidelines improves the standard of care: The Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006;113:ô 2398-2405.
Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 2007;116:721-728.
Nallamothu BK, Krumholz HM, Ko DT, LaBresh KA, Rathore S, Roe MT, et al. Development of systems of care for ST-elevation myocardial infarction patients: Gap, barriers, and implications. Circulation 2007;116: E68-e72.
Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: Description of the current situation in 30 countries. Eur Heart J 2010;31:943-957.
Knot J, Widimsky P, Wijns W, Stenestrand U, Kristensen SD, Van' T Hof A, et al. How to set up an effective national primary angioplasty network: Lessons learned from five European countries. EuroIntervention 2009;5:299301-309.
Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med 2006;355:2308-2320.
Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: Implications when selecting a reperfusion strategy. Circulation 2006;114:2019-2025.
Steg PG, Cambou JP, Goldstein P, Durand E, Sauval P, Kadri Z, et al. USIC 2000 Investigators. Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: The USIC 2000 registry. Heart 2006;92:1378-1383.
Wolff G, Dimitroulis D, Andreotti F, Kolodziejczak M, Jung C, Scicchitano P, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: A meta-analysis. Circ Heart Fail 2017;10: E003255.
Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, Beaver TM, et al. Influence of baseline characteristics, operative conduct, and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction: Results from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Circulation 2015;132:720-730.
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction: Everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation 2016;133: 2132-2140.
Nagendran J, Bozso SJ, Norris CM, McAlister FA, Appoo JJ, Moon MC, et al. Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol 2018; 71:819-827.
Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009;360: 1705-1717.
Oh JK, Velazquez EJ, Menicanti L, Pohost GM, Bonow RO, Lin G, et al. STICH Investigators. Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J 2013;34:39-47.
Dor V, Civaia F, Alexandrescu C, Sabatier M, Montiglio F. Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg 2011;141:905-916, 916 e1-e4.
Killip T, Passamani E, Davis K. Coronary artery surgery study (CASS): A randomized trial of coronary bypass surgery. Eight years follow-up and survival in patients with reduced ejection fraction. Circulation 1985;72: V102-V109.
Di Donato M, Castelvecchio S, Menicanti L. End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischaemic dilated cardiomyopathy. Eur J Heart Fail 2010;12: 375-381.
Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, et al. STICH Trial Investigators. Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg 2013;146:1139-1145.e6.
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999;341:625-634.
White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: Results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 2005;112:1992-2001.
Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) Trial Investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): Final 12 month results of a randomised, open-label trial. Lancet 2013; 382:1638-1645.
Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. IABP-SHOCK II Trial Investigators I-SIT. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287-1296.
Unverzagt S, Buerke M, de Waha A, Haerting J, Pietzner D, Seyfarth M, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev 2015;3:CD007398.
Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand WK, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: A systematic review and meta-analysis. Intensive Care Med 2016;42:1922-1934.
Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152: 469.e1-469.e8.
Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008;52:1584-1588.
Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: A systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017;38:3523-3531.
O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: The PROTECT II study. Circulation 2012;126:1717-1727.
Acharya D, Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, Holman WL, Cantor RS, et al. Ventricular assist device in acute myocardial infarction. J Am Coll Cardiol 2016;67:1871-1880.
Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, et al. SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006;295:2511-2515.
Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: Therapeutic options in patients with diabetes. J Am Coll Cardiol 2000;36:355-365.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003;108:1655-1661.
Ledru F, Ducimetiere P, Battaglia S, Courbon D, Beverelli F, Guize L, et al. New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol 2001;37: 1543-1550.
Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102: 2180-2184.
Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging 2012;5:S42-S52.
Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995;92:1731-1736
O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials. J Am Coll Cardiol 2012;60:106-111.
Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, et al. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ Cardiovasc Interv 2012;5:166-173.
Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, et al. FREEDOM Investigators. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: Results from the FREEDOM trial. J Am Coll Cardiol 2014;64:1189-1197.
Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010;254:261-269.
Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD, et al. The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: Five-year follow-up of the SYNTAX trial. EuroIntervention 2018;14:102-111.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44:1393-1399.
Ohno Y, Maekawa Y, Miyata H, Inoue S, Ishikawa S, Sueyoshi K, et al. Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention. J Am Coll Cardiol 2013;62:1260-1266.
Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, Nephrotoxicity in High-Risk Patients Study of I-O, Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in highrisk patients undergoing angiography. N Engl J Med 2003;348:491-499.
Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006;48:924-930.
Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: A randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007;115:3189-3196.
Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009;150:170-177.
Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, et al. Volume-to-creatinine clearance ratio: A pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:584-590.
Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004;291:2328-2334.
Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: A randomized trial. JAMA 2008;300:1038-1046.
Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): A prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017;389: 1312-1322.
Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, et al. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: Evidence from a hierarchical Bayesian network meta-analysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv 2017;10:e004383.
Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, et al. PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018;378:603-614.
Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv 2016;9:89-96.
Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. REMEDIAL II Investigators. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 2011;124:1260-1269.
Putzu A, Boscolo Berto M, Belletti A, Pasotti E, Cassina T, Moccetti T, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: A systematic review and meta-analysis of randomized trials. JACC Cardiovasc Interv 2017;10:355-363.
Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-1340.
Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006; 119:155-162.
Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: A systematic review. Am J Med 2012;125:66-78 e3.
Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001;111: 692-698.
Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Coronary physiology in patients with severe aortic stenosis: Comparison between fractional flow reserve and instantaneous wave-free ratio. Int J Cardiol 2017;243:40-46.
Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Physiologic evaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention 2018;13: 1512-1519.
Di Gioia G, Scarsini R, Strisciuglio T, De Biase C, Zivelonghi C, Franco D, et al. Correlation between angiographic and physiologic evaluation of coronary artery narrowings in patients with aortic valve stenosis. Am J Cardiol 2017;120:106-110.
Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2017;52: 616-664.
Yamashita K, Fujita T, Hata H, Shimahara Y, Kume Y, Matsumoto Y, et al. Long-term outcome of isolated off-pump coronary artery bypass grafting in patients with coronary artery disease and mild to moderate aortic stenosis. J Cardiol 2017;70:48-54.
Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 2016;374:344-353.
Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Cardiothoracic Surgical Trials Network Investigators. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2014; 371:2178-2188.
Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016;374:1932-1941.
Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al. RIME Investigators Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: Final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation 2012;126:2502-2510.
Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: An executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-644.
Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30: 303-371.
Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Stroke rates following surgical versus percutaneous coronary revascularization. J Am Coll Cardiol 2018;72:386-398.
Naylor AR, Bown MJ. Stroke after cardiac surgery and its association with asymptomatic carotid disease: An updated systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2011;41:607-624.
Naylor AR. Does the risk of post-CABG stroke merit staged or synchronous reconstruction in patients with symptomatic or asymptomatic carotid disease J Cardiovasc Surg (Torino) 2009;50:71-81.
Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: The European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763-816.
Lee R, Matsutani N, Polimenakos AC, Levers LC, Lee M, Johnson RG. Preoperative noncontrast chest computed tomography identifies potential aortic emboli. Ann Thorac Surg 2007;84:38-41.
Naylor AR, Cuffe RL, Rothwell PM, Bell PR. A systematic review of outcomes following staged and synchronous carotid endarterectomy and coronary artery bypass. Eur J Vasc Endovasc Surg 2003;25:380-389.
Paraskevas KI, Nduwayo S, Saratzis AN, Naylor AR. Carotid stenting prior to coronary bypass surgery: An updated systematic review and metaanalysis. Eur J Vasc Endovasc Surg 2017;53:309-319.
Lin JC, Kabbani LS, Peterson EL, Masabni K, Morgan JA, Brooks S, et al. Clinical utility of carotid duplex ultrasound prior to cardiac surgery. J Vasc Surg 2016;63:710-714.
Aboyans V, Lacroix P. Indications for carotid screening in patients with coronary artery disease. Presse Med 2009;38:977-986.
Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, et al. Cardiac Anesthesiology, and Interventional Cardiology Groups at the Vanderbilt Heart and Vascular Institute. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J Am Coll Cardiol 2009;53: 232-241.
Thielmann M, Massoudy P, Jaeger BR, Neuhauser M, Marggraf G, Sack S, et al. Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery. Eur J Cardiothorac Surg 2006;30:117-125.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infaction, et al. ESC Committee for Practice Guidelines. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-2567.
Davierwala PM, Verevkin A, Leontyev S, Misfeld M, Borger MA, Mohr FW. Impact of expeditious management of perioperative myocardial ischemia in patients undergoing isolated coronary artery bypass surgery. Circulation 2013;128:S226-S234.
Laflamme M, DeMey N, Bouchard D, Carrier M, Demers P, Pellerin M, et al. Management of early postoperative coronary artery bypass graft failure. Interact CardioVasc Thorac Surg 2012;14:452-456.
Gaudino M, Nesta M, Burzotta F, Trani C, Coluccia V, Crea F, et al. Results of emergency postoperative re-angiography after cardiac surgery procedures. Ann Thorac Surg 2015;99:1576-1582.
Thielmann M, Sharma V, Al-Attar N, Bulluck H, Bisleri G, Bunge JJH, et al. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. Eur Heart J 2017;38:2392-2407.
Seshadri N, Whitlow PL, Acharya N, Houghtaling P, Blackstone EH, Ellis SG. Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. Circulation 2002;106:2346-2350.
Mattichak SJ, Dixon SR, Shannon F, Boura JA, Safian RD. Failed percutaneous coronary intervention: A decade of experience in 21, 000 patients. Catheter Cardiovasc Interv 2008;71:131-137.
Davierwala PM, Leontyev S, Verevkin A, Rastan AJ, Mohr M, Bakhtiary F, et al. Temporal trends in predictors of early and late mortality after emergency coronary artery bypass grafting for cardiogenic shock complicating acute myocardial infarction. Circulation 2016;134:1224-1237.
Axelsson TA, Mennander A, Malmberg M, Gunn J, Jeppsson A, Gudbjartsson T. Is emergency and salvage coronary artery bypass grafting justified The Nordic Emergency/Salvage coronary artery bypass grafting study. Eur J Cardiothorac Surg 2016;49:1451-1456.
Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC, et al. Incidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: The SYNTAX trial at 5 years. JACC Cardiovasc Interv 2016;9:2493-2507.
Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014;100:153-159.
Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, et al. Risk of stent thrombosis among bare-metal stents first-generation drug-eluting stentsand second-generation drug-eluting stents: Results from a registry of 18, 334 patients. JACC Cardiovasc Interv 2013;6:1267-1274.
Sabik JF III, Blackstone EH, Houghtaling PL, Walts PA, Lytle BW. Is reoperation still a risk factor in coronary artery bypass surgery Ann Thorac Surg 2005;80:1719-1727.
Yap CH, Sposato L, Akowuah E, Theodore S, Dinh DT, Shardey GC, et al. Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality. Ann Thorac Surg 2009;87: 1386-1391.
Fosbol EL, Zhao Y, Shahian DM, Grover FL, Edwards FH, Peterson ED. Repeat coronary revascularization after coronary artery bypass surgery in older adults: The Society of Thoracic Surgeons' national experience, 1991-2007. Circulation 2013;127:1656-1663.
Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J 2006;27:413-418.
Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, et al. Investigators of the Department of Veterans Affairs Cooperative Study #385. Angina With Extremely Serious Operative Mortality Evaluation. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002;40:1951-1954.
Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, et al. Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: A multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 2001;38:143-149.
Harskamp RE, Beijk MA, Damman P, Kuijt WJ, Woudstra P, Grundeken MJ, et al. Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. J Cardiovasc Med (Hagerstown) 2013;14:438-445.
Sabik JF III, Raza S, Blackstone EH, Houghtaling PL, Lytle BW. Value of internal thoracic artery grafting to the left anterior descending coronary artery at coronary reoperation. J Am Coll Cardiol 2013;61:302-310.
Nwaejike N, Tennyson C, Mosca R, Venkateswaran R. Reusing the patent internal mammary artery as a conduit in redo coronary artery bypass surgery. Interact CardioVasc Thorac Surg 2016;22:346-350.
Coolong A, Baim DS, Kuntz RE, O'Malley AJ, Marulkar S, Cutlip DE, et al. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008;117:790-797.
Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, et al. Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aortocoronary bypass grafts. Circulation 2002;105:1285-1290.
Paul TK, Bhatheja S, Panchal HB, Zheng S, Banerjee S, Rao SV, et al. Outcomes of saphenous vein graft intervention with and without embolic protection device: A comprehensive review and meta-analysis. Circ Cardiovasc Interv 2017;10:e005538.
Brennan JM, Al-Hejily W, Dai D, Shaw RE, Trilesskaya M, Rao SV Jr., et al. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: Results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. Circ Cardiovasc Interv 2015;8:e001403.
Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, et al. FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003; 108:548-553.
Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, et al. The PROXIMAL trial: Proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: A randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007;50:1442-1449.
Schachinger V, Hamm CW, Munzel T, Haude M, Baldus S, Grube E, et al. STENTS (STents IN Grafts) Investigators. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003;42:1360-1369.
Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C, et al. Randomized evaluation of polytetrafluoroethylenecovered stent in saphenous vein grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation 2003;108:37-42.
Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, et al. Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts (ISAR CABG) Investigators. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): A randomised controlled superiority trial. Lancet 2011;378:1071-1078.
Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009;53: 919-928.
Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, et al. DELAYED RRISC Investigators. Randomized doubleblind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006;48:2423-2431.
Colleran R, Kufner S, Mehilli J, Rosenbeiger C, Schupke S, Hoppmann P, et al. ISAR-CABG Investigators. Efficacy over time with drug-eluting stents in saphenous vein graft lesions. J Am Coll Cardiol 2018;71: 1973-1982.
Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, et al. Continued benefit from paclitaxel-eluting compared with baremetal stent implantation in saphenous vein graft lesions during longterm follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011;4:176-182.
Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al. DELAYED RRISC (Death and Events at Longterm follow-up AnalYsis: Extended Duration of the Reduction of Restenosis in Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007;50:261-267.
Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, et al. ISARDESIRE 2 Investigators. Randomized trial of paclitaxel-versus sirolimuseluting stents for treatment of coronary restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55:2710-2716.
Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. ISAR-DESIRE Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005;293:165-171.
Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, et al. RIBS-II Investigators. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with instent restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006;47:2152-2160.
Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, Lopez-Minguez JR, et al. Restenosis Intra-stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003;42:796-805.
Dibra A, Kastrati A, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J, et al. Effectiveness of drug-eluting stents in patients with bare-metal instent restenosis: Meta-analysis of randomized trials. J Am Coll Cardiol 2007;49:616-623.
Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv 2012; 5:323-330.
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-2124.
Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J 2013;166:527-533.
Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxelcoated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986-2994.
Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: The PEPCAD-DES study. J Am Coll Cardiol 2012;59:1377-1382.
Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 2011;4: 149-154.
Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. ISARDESIRE 3 Investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, openlabel trial. Lancet 2013;381:461-467.
Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, et al. Drug-eluting balloon angioplasty for in-stent restenosis: A systematic review and meta-analysis of randomised controlled trials. Heart 2013;99:ô 327-333.
Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Seidelberger B, Iniguez A, et al. RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drugeluting balloon versus everolimus-eluting stent in patients with baremetal stent-in-stent restenosis: The RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting balloon vs everolimus-eluting stent). J Am Coll Cardiol 2014;63:1378-1386.
Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimuseluting stents in the treatment of coronary in-stent restenosis: The treatment of in-stent restenosis study. Circ Cardiovasc Interv 2016;9: E003316.
Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. RIBS IV Investigators. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drugeluting stents: The RIBS IV randomized clinical trial. J Am Coll Cardiol 2015;66:23-33.
Baan J Jr, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: The DARE trial. JACC Cardiovasc Interv 2018;11:275-283.
Kufner S, Joner M, Schneider S, Tolg R, Zrenner B, Repp J, et al. ISARDESIRE 4 Investigators. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: A randomized controlled trial. JACC Cardiovasc Interv 2017;10:1332-1340.
Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: A network meta-analysis. Lancet 2015; 386:655-664.
Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: Systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ 2015;351:h5392.
Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schupke S, Hoppmann P, et al. ISAR-DESIRE 3 Investigators. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. JACC Cardiovasc Interv 2015;8:877-884.
Xu B, Qian J, Ge J, Wang J, Chen F, Chen J, et al. PEPCAD China ISR Investigators. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Catheter Cardiovasc Interv 2016;87:624-629.
Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; Evidence in support of drug resistance: Insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention 2013;9:797-802.
Zellweger MJ, Kaiser C, Jeger R, Brunner-La Rocca HP, Buser P, Bader F, et al. Coronary artery disease progression late after successful stent implantation. J Am Coll Cardiol 2012;59:793-799.
Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226-235.
Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 2008;51: 2396-23402.
Alfonso F, Dutary J, Paulo M, Gonzalo N, Perez-Vizcayno MJ, Jimenez-Quevedo P, et al. Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. Heart 2012;98:1213-1220.
Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, et al. Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Optical coherence tomography findings in patients with coronary stent thrombosis: A report of the PRESTIGE Consortium review. Circulation 2017;136:1007-1021.
Armstrong EJ, Feldman DN, Wang TY, Kaltenbach LA, Yeo KK, Wong SC, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012;5:131-140.
Holmes DR Jr, Davis KB, Mock MB, Fisher LD, Gersh BJ, Killip T III, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: A report from the Coronary Artery Surgery Study. Circulation 1986;73:1254-1263.
Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet 1982;2:1173-80.
Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ, Exner DV. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 2001;104: 1489-1493.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346: 877-883.
Al-Khatib SM, Hellkamp AS, Lee KL, Anderson J, Poole JE, Mark DB, et al. SCD-HeFT Investigators. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). J Cardiovasc Electrophysiol 2008;19:1059-1065.
Sesselberg HW, Moss AJ, McNitt S, Zareba W, Daubert JP, Andrews ML, et al. MADIT II Research Group. Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: A MADIT-II substudy. Heart Rhythm 2007;4: 1395-1402.
Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut JF, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997;336:1629-1633.
Kern KB. Optimal treatment of patients surviving out-of-hospital cardiac arrest. JACC Cardiovasc Interv 2012;5:597-605.
Garot P, Lefevre T, Eltchaninoff H, Morice MC, Tamion F, Abry B, et al. Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. Circulation 2007;115:1354-1362.
Radsel P, Knafelj R, Kocjancic S, Noc M. Angiographic characteristics of coronary disease and postresuscitation electrocardiograms in patients with aborted cardiac arrest outside a hospital. Am J Cardiol 2011;108: 634-638.
Anyfantakis ZA, Baron G, Aubry P, Himbert D, Feldman LJ, Juliard JM, et al. Acute coronary angiographic findings in survivors of out-ofhospital cardiac arrest. Am Heart J 2009;157:312-318.
Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: Insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200-207.
Cronier P, Vignon P, Bouferrache K, Aegerter P, Charron C, Templier F, et al. Impact of routine percutaneous coronary intervention after outof-hospital cardiac arrest due to ventricular fibrillation. Crit Care 2011; 15:R122.
Geri G, Dumas F, Bougouin W, Varenne O, Daviaud F, Pene F, et al. Immediate percutaneous coronary intervention is associated with improved short- A nd long-term survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv 2015;8:e002303.
Vyas A, Chan PS, Cram P, Nallamothu BK, McNally B, Girotra S. Early coronary angiography and survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv 2015;8:e002321.
Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, et al. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: A consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups. EuroIntervention 2014;10:31-37.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50:e1-e88.
Chan W, Ajani AE, Clark DJ, Stub D, Andrianopoulos N, Brennan AL, et al. Melbourne Interventional Group Investigators. Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention. Am J Cardiol 2012;109:471-477.
Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: Results from the APEX-AMI trial. Eur Heart J 2009;30:2019-2028.
Mrdovic I, Savic L, Krljanac G, Perunicic J, Asanin M, Lasica R, et al. Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: Insight into the RISK-PCI trial. Coron Artery Dis 2012;23:1-8.
Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, Mattle H, et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. EuroIntervention 2013;8:1061-1071.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2018;53:34-78.
Ahlsson AJ, Bodin L, Lundblad OH, Englund AG. Postoperative atrial fibrillation is not correlated to C-reactive protein. Ann Thorac Surg 2007;83:1332-1337.
Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013;1: CD003611.
Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291:1720-1729.
Shen J, Lall S, Zheng V, Buckley P, Damiano RJ Jr, Schuessler RB. The persistent problem of new-onset postoperative atrial fibrillation: A singleinstitution experience over two decades. J Thorac Cardiovasc Surg 2011; 141:559-570.
LaPar DJ, Speir AM, Crosby IK, Fonner E Jr, Brown M, Rich JB, et al. Investigators for the Virginia Cardiac Surgery Quality Initiative. Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg 2014;98:527-533.
Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19, 497 patients). Am J Cardiol 2012;109:219-225.
Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL, et al. Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: Insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. Clin Cardiol 2014;37:7-13.
Ahlsson A, Bodin L, Fengsrud E, Englund A. Patients with postoperative atrial fibrillation have a doubled cardiovascular mortality. Scand Cardiovasc J 2009;43:330-336.
Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg 2010;37:1353-1359.
Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014;312:616-622.
Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008;118:1612-1618.
Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004;43:742-748.
Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of postoperative atrial fibrillation and its complications after cardiac surgery: A meta-analysis. Eur Heart J 2006;27:2846-2857.
Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O'Brien B, Carroll S, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The beta-Blocker Length Of Stay (BLOS) study. Am Heart J 2003;145: 226-232.
Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: A meta-analysis. Circulation 2002;106:75-80.
Dunning J, Treasure T, Versteegh M, Nashef SA, EACTS Audit and Guidelines Committee. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006;30:852-872.
Koniari I, Apostolakis E, Rogkakou C, Baikoussis NG, Dougenis D. Pharmacologic prophylaxis for atrial fibrillation following cardiac surgery: A systematic review. J Cardiothorac Surg 2010;5:121.
Lucio Ede A, Flores A, Blacher C, Leaes PE, Lucchese FA, Ribeiro JP. Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery. Arq Bras Cardiol 2004;82:42-46, 37-41.
Tsuboi J, Kawazoe K, Izumoto H, Okabayashi H. Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. Circ J 2008;72:588-591.
Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the management of postoperative atrial fibrillation. Clin Lab Med 2014;34:537-561.
El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 2010;55:1370-1376.
Melduni RM, Schaff HV, Lee HC, Gersh BJ, Noseworthy PA, Bailey KR, et al. Impact of left atrial appendage closure during cardiac surgery on the occurrence of early postoperative atrial fibrillationstroke, and mortality: A propensity score-matched analysis of 10 633 patients. Circulation 2017;135:366-378.
Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: A meta-analysis. Eur J Cardiothorac Surg 2015;47:847-854.
Friedman DJ, Piccini JP, Wang T, Zheng J, Malaisrie SC, Holmes DR, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery. JAMA 2018;319:365-374.
Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, et al. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Ann Cardiothorac Surg 2014;3:45-54.
Kern KB, Rahman O. Emergent percutaneous coronary intervention for resuscitated victims of out-of-hospital cardiac arrest. Catheter Cardiovasc Interv 2010;75:616-624.
Garcia-Tejada J, Jurado-Roman A, Rodriguez J, Velazquez M, Hernandez F, Albarran A, et al. Post-resuscitation electrocardiograms, acute coronary findings and in-hospital prognosis of survivors of out-of-hospital cardiac arrest. Resuscitation 2014;85:1245-1250.
Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: Efficacy of prophylactic betablockers in the modern era: A meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol 2013;18:58-68.
Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: A network regression meta-analysis. Pacing Clin Electrophysiol 2013;36:1017-1023.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33: 1500-1510.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;137:263-272.
Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 2016;374:1911-1921.
Head SJ, Milojevic M, Taggart DP, Puskas JD. Current practice of stateof-the-art surgical coronary revascularization. Circulation 2017;136: 1331-1345.
Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Pagano D, Milojevic M, Meesters MI, Benedetto U, Bolliger D, von Heymann C, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018;53: 79-111.
Head SJ, Mack MJ, Holmes DR Jr, Mohr FW, Morice MC, Serruys PW, et al. Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: A subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg 2012;41:535-541.
Kim YH, Park DW, Lee JY, Kim WJ, Yun SC, Ahn JM, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation 2011;123:2373-2381.
Mohammadi S, Kalavrouziotis D, Dagenais F, Voisine P, Charbonneau E. Completeness of revascularization and survival among octogenarians with triple-vessel disease. Ann Thorac Surg 2012;93:1432-1437.
Rastan AJ, Walther T, Falk V, Kempfert J, Merk D, Lehmann S, et al. Does reasonable incomplete surgical revascularization affect early or longterm survival in patients with multivessel coronary artery disease receiving left internal mammary artery bypass to left anterior descending artery Circulation 2009;120:S70-S77.
Yi G, Youn YN, Joo HC, Hong S, Yoo KJ. Association of incomplete revascularization with long-term survival after off-pump coronary artery bypass grafting. J Surg Res 2013;185:166-173.
Scott R, Blackstone EH, McCarthy PM, Lytle BW, Loop FD, White JA, et al. Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery: Late consequences of incomplete revascularization. J Thorac Cardiovasc Surg 2000;120:173-184.
Melby SJ, Saint LL, Balsara K, Itoh A, Lawton JS, Maniar H, et al. Complete coronary revascularization improves survival in octogenarians. Ann Thorac Surg 2016;102:505-511.
Botman CJ, Schonberger J, Koolen S, Penn O, Botman H, Dib N, et al. Does stenosis severity of native vessels influence bypass graft patency A prospective fractional flow reserve-guided study. Ann Thorac Surg 2007;83:2093-2097.
Boylan MJ, Lytle BW, Loop FD, Taylor PC, Borsh JA, Goormastic M, et al. Surgical treatment of isolated left anterior descending coronary stenosis. Comparison of left internal mammary artery and venous autograft at 18 to 20 years of follow-up. J Thorac Cardiovasc Surg 1994;107:657-662.
Sabik JF III, Blackstone EH, Gillinov AM, Banbury MK, Smedira NG, Lytle BW. Influence of patient characteristics and arterial grafts on freedom from coronary reoperation. J Thorac Cardiovasc Surg 2006;131:90-98.
Schmitto JD, Rajab TK, Cohn LH. Prevalence and variability of internal mammary graft use in contemporary multivessel coronary artery bypass graft. Curr Opin Cardiol 2010;25:609-612.
Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, et al. Saphenous vein graft failure after coronary artery bypass surgery: Insights from PREVENT IV. Circulation 2014;130:1445-1451.
Benedetto U, Raja SG, Albanese A, Amrani M, Biondi-Zoccai G, Frati G. Searching for the second best graft for coronary artery bypass surgery: A network meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg 2015;47:59-65.
Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral internal mammary artery grafting enhances survival in diabetic patients: A 30-year follow-up of propensity score-matched cohorts. Circulation 2012;126:2935-2942.
Galbut DL, Kurlansky PA, Traad EA, Dorman MJ, Zucker M, Ebra G. Bilateral internal thoracic artery grafting improves long-term survival in patients with reduced ejection fraction: A propensity-matched study with 30-year follow-up. J Thorac Cardiovasc Surg 2012;143:844-853.e4.
Grau JB, Ferrari G, Mak AW, Shaw RE, Brizzio ME, Mindich BP, et al. Propensity matched analysis of bilateral internal mammary artery versus single left internal mammary artery grafting at 17-year follow-up: Validation of a contemporary surgical experience. Eur J Cardiothorac Surg 2012;41: 770-775.
Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. Ann Thorac Surg 2010;90: 101-108.
Ruttmann E, Fischler N, Sakic A, Chevtchik O, Alber H, Schistek R, et al. Second internal thoracic artery versus radial artery in coronary artery bypass grafting: A long-term, propensity score-matched follow-up study. Circulation 2011;124:1321-1329.
Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: A systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 2001;358:870-875.
Weiss AJ, Zhao S, Tian DH, Taggart DP, Yan TD. A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting. Ann Cardiothorac Surg 2013; 2:390-400.
Gaudino M, Di Franco A, Rahouma M, Tam DY, Iannaccone M, Deb S, et al. Unmeasured confounders in observational studies comparing bilateral versus single internal thoracic artery for coronary artery bypass grafting: A meta-analysis. J Am Heart Assoc 2018;7:e008010.
Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, et al. Arterial Revascularization Trial Investigators. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med 2016;375: 2540-2549.
Gaudino M, Tranbaugh R, Fremes S. Bilateral versus single internalthoracic- A rtery grafts. N Engl J Med 2017;376:e37.
Raza S, Blackstone EH, Sabik JF III. Bilateral versus single internalthoracic- A rtery grafts. N Engl J Med 2017;376:e37.
Royse A, Eccleston D, Royse C, iGRAFT Collaborators. Bilateral versus single internal-thoracic-artery grafts. N Engl J Med 2017;376:e37.
Deo SV, Shah IK, Dunlay SM, Erwin PJ, Locker C, Altarabsheh SE, et al. Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients. Ann Thorac Surg 2013;95:862-869.
Elmistekawy EM, Gawad N, Bourke M, Mesana T, Boodhwani M, Rubens FD. Is bilateral internal thoracic artery use safe in the elderly J Card Surg 2012;27:1-5.
Hemo E, Mohr R, Uretzky G, Katz G, Popovits N, Pevni D, et al. Longterm outcomes of patients with diabetes receiving bilateral internal thoracic artery grafts. J Thorac Cardiovasc Surg 2013;146:586-592.
Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon KART Investigators. Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation[ISRCTN46552265]. Trials 2006;7:7.
Toumpoulis IK, Theakos N, Dunning J. Does bilateral internal thoracic artery harvest increase the risk of mediastinitis Interact CardioVasc Thorac Surg 2007;6:787-791.
Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Pawlaczyk R, et al. Arterial Revascularization Trial Investigators. Pedicled and skeletonized single and bilateral internal thoracic artery grafts and the incidence of sternal wound complications: Insights from the Arterial Revascularization Trial. J Thorac Cardiovasc Surg 2016;152:270-276.
Hayward PA, Gordon IR, Hare DL, Matalanis G, Horrigan ML, Rosalion A, et al. Comparable patencies of the radial artery and right internal thoracic artery or saphenous vein beyond 5 years: Results from the Radial Artery Patency and Clinical Outcomes trial. J Thorac Cardiovasc Surg 2010;139:60-5; discussion 65-67.
Schwann TA, Engoren M, Bonnell M, Clancy C, Habib RH. Comparison of late coronary artery bypass graft survival effects of radial artery versus saphenous vein grafting in male and female patients. Ann Thorac Surg 2012;94:1485-1491.
Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, et al. Radial artery conduits improve long-term survival after coronary artery bypass grafting. Ann Thorac Surg 2010;90:1165-1172.
Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, et al. Coronary artery bypass grafting using the radial artery: Clinical outcomes, patency, and need for reintervention. Circulation 2012;126: S170-S175.
Cao C, Manganas C, Horton M, Bannon P, Munkholm-Larsen S, Ang SC, et al. Angiographic outcomes of radial artery versus saphenous vein in coronary artery bypass graft surgery: A meta-analysis of randomized controlled trials. J Thorac Cardiovasc Surg 2013;146:255-261.
Gaudino M, Benedetto U, Fremes S, Biondi-Zoccai G, Sedrakyan A, Puskas JD, et al. RADIAL Investigators. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med 2018;378: 2069-2077.
Sa MP, Ferraz PE, Escobar RR, Vasconcelos FP, Ferraz AA, Braile DM, et al. Skeletonized versus pedicled internal thoracic artery and risk of sternal wound infection after coronary bypass surgery: Meta-analysis and meta-regression of 4817 patients. Interact CardioVasc Thorac Surg 2013;16:849-857.
Sakic A, Chevtchik O, Kilo J, Schistek R, Mueller LC, Ulmer H, et al. Simple adaptations of surgical technique to critically reduce the risk of postoperative sternal complications in patients receiving bilateral internal thoracic arteries. Interact CardioVasc Thorac Surg 2013;17:378-382.
Wendler O, Hennen B, Markwirth T, Konig J, Tscholl D, Huang Q, et al. T grafts with the right internal thoracic artery to left internal thoracic artery versus the left internal thoracic artery and radial artery: Flow dynamics in the internal thoracic artery main stem. J Thorac Cardiovasc Surg 1999;118: 841-848.
Kajimoto K, Yamamoto T, Amano A. Coronary artery bypass revascularization using bilateral internal thoracic arteries in diabetic patients: A systematic review and meta-analysis. Ann Thorac Surg 2015;99:1097-1104.
Sa MP, Cavalcanti PE, Santos HJ, Soares AF, Miranda RG, Araujo ML, et al. Flow capacity of skeletonized versus pedicled internal thoracic artery in coronary artery bypass graft surgery: Systematic review, metaanalysis and meta-regression. Eur J Cardiothorac Surg 2015;48:25-31.
Navia JL, Olivares G, Ehasz P, Gillinov AM, Svensson LG, Brozzi N, et al. Endoscopic radial artery harvesting procedure for coronary artery bypass grafting. Ann Cardiothorac Surg 2013;2:557-564.
Cao C, Tian DH, Ang SC, Peeceeyen S, Allan J, Fu B, et al. A metaanalysis of endoscopic versus conventional open radial artery harvesting for coronary artery bypass graft surgery. Innovations (Phila) 2014;9: 269-275.
Gaudino M, Leone A, Lupascu A, Toesca A, Mazza A, Ponziani FR, et al. Morphological and functional consequences of transradial coronary angiography on the radial artery: Implications for its use as a bypass conduit. Eur J Cardiothorac Surg 2015;48:370-374.
Ouzounian M, Hassan A, Buth KJ, MacPherson C, Ali IM, Hirsch GM, et al. Impact of endoscopic versus open saphenous vein harvest techniques on outcomes after coronary artery bypass grafting. Ann Thorac Surg 2010;89:403-408.
Yun KL, Wu Y, Aharonian V, Mansukhani P, Pfeffer TA, Sintek CF, et al. Randomized trial of endoscopic versus open vein harvest for coronary artery bypass grafting: Six-month patency rates. J Thorac Cardiovasc Surg 2005;129:496-503.
Chernyavskiy A, Volkov A, Lavrenyuk O, Terekhov I, Kareva Y. Comparative results of endoscopic and open methods of vein harvesting for coronary artery bypass grafting: A prospective randomized parallel-group trial. J Cardiothorac Surg 2015;10:163.
Krishnamoorthy B, Critchley WR, Glover AT, Nair J, Jones MT, Waterworth PD, et al. A randomized study comparing three groups of vein harvesting methods for coronary artery bypass grafting: Endoscopic harvest versus standard bridging and open techniques. Interact CardioVasc Thorac Surg 2012;15:224-228.
Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, et al. Endoscopic versus open vein-graft harvesting in coronaryartery bypass surgery. N Engl J Med 2009;361:235-244.
Zenati MA, Shroyer AL, Collins JF, Hattler B, Ota T, Almassi GH, et al. Impact of endoscopic versus open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. J Thorac Cardiovasc Surg 2011;141: 338-434.
Deppe AC, Liakopoulos OJ, Choi YH, Slottosch I, Kuhn EW, Scherner M, et al. Endoscopic vein harvesting for coronary artery bypass grafting: A systematic review with meta-analysis of 27789 patients. J Surg Res 2013; 180:114-124.
Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavris D, Alexander JH, et al. Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA 2012;308:475-484.
Brown EN, Kon ZN, Tran R, Burris NS, Gu J, Laird P, et al. Strategies to reduce intraluminal clot formation in endoscopically harvested saphenous veins. J Thorac Cardiovasc Surg 2007;134:1259-1265.
Khaleel MS, Dorheim TA, Duryee MJ, Durbin HE Jr, Bussey WD, Garvin RP, et al. High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: A potential mechanism for graft failure. Ann Thorac Surg 2012;93:552-558.
Rousou LJ, Taylor KB, Lu XG, Healey N, Crittenden MD, Khuri SF, et al. Saphenous vein conduits harvested by endoscopic technique exhibit structural and functional damage. Ann Thorac Surg 2009;87:62-70.
Johansson BL, Souza DS, Bodin L, Filbey D, Loesch A, Geijer H, et al. Slower progression of atherosclerosis in vein grafts harvested with 'touch' technique compared with conventional harvesting technique in coronary artery bypass grafting: An angiographic and intravascular ultrasound study. Eur J Cardiothorac Surg 2010;38:414-419.
Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, et al. Improved patency in vein grafts harvested with surrounding tissue: Results of a randomized study using three harvesting techniques. Ann Thorac Surg 2002;73:1189-1195.
Dreifaldt M, Mannion JD, Bodin L, Olsson H, Zagozdzon L, Souza D. The no-touch saphenous vein as the preferred second conduit for coronary artery bypass grafting. Ann Thorac Surg 2013;96:105-111.
Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The notouch saphenous vein for coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic artery: A randomized trial. J Thorac Cardiovasc Surg 2015;150:880-888.
Emmert MY, Seifert B, Wilhelm M, Grunenfelder J, Falk V, Salzberg SP. Aortic no-touch technique makes the difference in off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 2011;142:1499-1506.
Borgermann J, Hakim K, Renner A, Parsa A, Aboud A, Becker T, et al. Clampless off-pump versus conventional coronary artery revascularization: A propensity score analysis of 788 patients. Circulation 2012;126: S176-S182.
Misfeld M, Brereton RJ, Sweetman EA, Doig GS. Neurologic complications after off-pump coronary artery bypass grafting with and without aortic manipulation: Meta-analysis of 11, 398 cases from 8 studies. J Thorac Cardiovasc Surg 2011;142:e11-e17.
Guerrieri Wolf L, Abu-Omar Y, Choudhary BP, Pigott D, Taggart DP. Gaseous and solid cerebral microembolization during proximal aortic anastomoses in off-pump coronary surgery: The effect of an aortic sidebiting clamp and two clampless devices. J Thorac Cardiovasc Surg 2007; 133:485-493.
El Zayat H, Puskas JD, Hwang S, Thourani VH, Lattouf OM, Kilgo P, et al. Avoiding the clamp during off-pump coronary artery bypass reduces cerebral embolic events: Results of a prospective randomized trial. Interact CardioVasc Thorac Surg 2012;14:12-16.
Kieser TM, Rose S, Kowalewski R, Belenkie I. Transit-time flow predicts outcomes in coronary artery bypass graft patients: A series of 1000 consecutive arterial grafts. Eur J Cardiothorac Surg 2010;38:155-162.
Mujanovic E, Kabil E, Bergsland J. Transit time flowmetry in coronary surgery-an important tool in graft verification. Bosn J Basic Med Sci 2007;7:275-8.
Jokinen JJ, Werkkala K, Vainikka T, Perakyla T, Simpanen J, Ihlberg L. Clinical value of intra-operative transit-time flow measurement for coronary artery bypass grafting: A prospective angiography-controlled study. Eur J Cardiothorac Surg 2011;39:918-923.
Lehnert P, Moller CH, Damgaard S, Gerds TA, Steinbruchel DA. Transittime flow measurement as a predictor of coronary bypass graft failure at one year angiographic follow-up. J Card Surg 2015;30:47-52.
Niclauss L. Techniques and standards in intraoperative graft verification by transit time flow measurement after coronary artery bypass graft surgery: A critical review. Eur J Cardiothorac Surg 2017;51:26-33.
Diegeler A, Borgermann J, Kappert U, Breuer M, Boning A, Ursulescu A, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med 2013;368:1189-1198.
Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al. CORONARY Investigators. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med 2012;366:1489-1497.
Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al. CORONARY Investigators. Effects of off-pump and on-pump coronary- A rtery bypass grafting at 1 year. N Engl J Med 2013;368: 1179-1188.
Hattler B, Messenger JC, Shroyer AL, Collins JF, Haugen SJ, Garcia JA, et al. Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. Off-pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation 2012;125:2827-2835.
Houlind K, Kjeldsen BJ, Madsen SN, Rasmussen BS, Holme SJ, Nielsen PH, et al. DOORS Group. On-pump versus off-pump coronary artery bypass surgery in elderly patients: Results from the Danish onpump versus off-pump randomization study. Circulation 2012;125: 2431-2439.
Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, et al. Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med 2009;361:1827-1837.
Keeling WB, Kilgo PD, Puskas JD, Halkos ME, Lattouf OM, Guyton RA, et al. Off-pump coronary artery bypass grafting attenuates morbidity and mortality for patients with low and high body mass index. J Thorac Cardiovasc Surg 2013;146:1442-1448.
Puskas JD, Thourani VH, Kilgo P, Cooper W, Vassiliades T, Vega JD, et al. Off-pump coronary artery bypass disproportionately benefits high-risk patients. Ann Thorac Surg 2009;88:1142-1147.
Puskas JD, Williams WH, O'Donnell R, Patterson RE, Sigman SR, Smith AS, et al. Off-pump and on-pump coronary artery bypass grafting are associated with similar graft patency, myocardial ischemia, and freedom from reintervention: Long-term follow-up of a randomized trial. Ann Thorac Surg 2011;91:1836-1842; discussion 1842-1843.
Sedrakyan A, Wu AW, Parashar A, Bass EB, Treasure T. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: A metaanalysis of systematically reviewed trials. Stroke 2006;37:2759-2769.
Altarabsheh SE, Deo SV, Rababa'h AM, Lim JY, Cho YH, Sharma V, et al. Off-pump coronary artery bypass reduces early stroke in octogenarians: A meta-analysis of 18000 patients. Ann Thorac Surg 2015;99:1568-1575.
Chawla LS, Zhao Y, Lough FC, Schroeder E, Seneff MG, Brennan JM. Offpump versus on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function. J Am Soc Nephrol 2012;23: 1389-1397.
Head SJ, Borgermann J, Osnabrugge RL, Kieser TM, Falk V, Taggart DP, et al. Coronary artery bypass grafting: Part 2-optimizing outcomes and future prospects. Eur Heart J 2013;34:2873-2886.
Diegeler A, Walther T, Metz S, Falk V, Krakor R, Autschbach R, et al. Comparison of MIDCAP versus conventional CABG surgery regarding pain and quality of life. Heart Surg Forum 1999;2:290-5; discussion 295-296.
Groh MA, Sutherland SE, Burton HG III, Johnson AM, Ely SW. Portaccess coronary artery bypass grafting: Technique and comparative results. Ann Thorac Surg 1999;68:1506-1508.
Lapierre H, Chan V, Sohmer B, Mesana TG, Ruel M. Minimally invasive coronary artery bypass grafting via a small thoracotomy versus offpump: A case-matched study. Eur J Cardiothorac Surg 2011;40:804-810.
Deppe AC, Liakopoulos OJ, Kuhn EW, Slottosch I, Scherner M, Choi YH, et al. Minimally invasive direct coronary bypass grafting versus percutaneous coronary intervention for single-vessel disease: A meta-analysis of 2885 patients. Eur J Cardiothorac Surg 2015;47:397-406.
Wang XW, Qu C, Huang C, Xiang XY, Lu ZQ. Minimally invasive direct coronary bypass compared with percutaneous coronary intervention for left anterior descending artery disease: A meta-analysis. J Cardiothorac Surg 2016;11:125.
Gasior M, Zembala MO, Tajstra M, Filipiak K, Gierlotka M, Hrapkowicz T, et al. POL-MIDES (HYBRID) Investigators. Hybrid revascularization for multivessel coronary artery disease. JACC Cardiovasc Interv 2014;7: 1277-1283.
Bonatti JO, Zimrin D, Lehr EJ, Vesely M, Kon ZN, Wehman B, et al. Hybrid coronary revascularization using robotic totally endoscopic surgery: Perioperative outcomes and 5-year results. Ann Thorac Surg 2012; 94:1920-1926.
Shen L, Hu S, Wang H, Xiong H, Zheng Z, Li L, et al. One-stop hybrid coronary revascularization versus coronary artery bypass grafting and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution. J Am Coll Cardiol 2013;61:2525-2533.
Harskamp RE, Bonatti JO, Zhao DX, Puskas JD, de Winter RJ, Alexander JH, et al. Standardizing definitions for hybrid coronary revascularization. J Thorac Cardiovasc Surg 2014;147:556-560.
Zembala M, Tajstra M, Zembala M, Filipiak K, Knapik P, Hrapkowicz T, et al. Prospective randomised pilOt study evaLuating the safety and efficacy of hybrid revascularisation in MultI-vessel coronary artery DisEaSe (POLMIDES)-study design. Kardiol Pol 2011;69:460-466.
Tajstra M, Hrapkowicz T, Hawranek M, Filipiak K, Gierlotka M, Zembala M, et al. POL-MIDES Study Investigators. Hybrid coronary revascularization in selected patients with multivessel disease: 5-year clinical outcomes of the prospective randomized pilot study. JACC Cardiovasc Interv 2018;11: 847-852
Panoulas VF, Colombo A, Margonato A, Maisano F. Hybrid coronary revascularization: Promising, but yet to take off. J Am Coll Cardiol 2015; 65:85-97.
Siregar S, Groenwold RH, de Mol BA, Speekenbrink RG, Versteegh MI, Brandon Bravo Bruinsma GJ, et al. Evaluation of cardiac surgery mortality rates: 30-day mortality or longer follow-up Eur J Cardiothorac Surg 2013;44:875-883.
Zhao DF, Edelman JJ, Seco M, Bannon PG, Wilson MK, Byrom MJ, et al. Coronary artery bypass grafting with and without manipulation of the ascending aorta: A network meta-analysis. J Am Coll Cardiol 2017;69: 924-936.
Moss E, Puskas JD, Thourani VH, Kilgo P, Chen EP, Leshnower BG, et al. Avoiding aortic clamping during coronary artery bypass grafting reduces postoperative stroke. J Thorac Cardiovasc Surg 2015;149:175-180.
Hlatky MA, Boothroyd DB, Reitz BA, Shilane DA, Baker LC, Go AS. Adoption and effectiveness of internal mammary artery grafting in coronary artery bypass surgery among Medicare beneficiaries. J Am Coll Cardiol 2014;63:33-39.
Kieser TM, Lewin AM, Graham MM, Martin BJ, Galbraith PD, Rabi DM, et al. APPROACH Investigators. Outcomes associated with bilateral internal thoracic artery grafting: The importance of age. Ann Thorac Surg 2011;92:1269-1275; discussion 1275-1276.
Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary artery grafts on long-term survival: A meta-analysis approach. Circulation 2014;130:539-545.
Taggart DP, Altman DG, Flather M, Gerry S, Gray A, Lees B, et al. ART (Arterial Revascularization Trial) Investigators. Associations between adding a radial artery graft to single and bilateral internal thoracic artery grafts and outcomes: Insights from the Arterial Revascularization Trial. Circulation 2017;136:454-463.
Yamasaki M, Deb S, Tsubota H, Moussa F, Kiss A, Cohen EA, et al. Radial Artery Patency Study Investigators. Comparison of radial artery and saphenous vein graft stenosis more than 5 years after coronary artery bypass grafting. Ann Thorac Surg 2016;102:712-719.
Benedetto U, Amrani M, Raja SG, Harefield Cardiac Outcomes Research Group. Guidance for the use of bilateral internal thoracic arteries according to survival benefit across age groups. J Thorac Cardiovasc Surg 2014;148: 2706-2711.
Desai ND, Cohen EA, Naylor CD, Fremes SE, Radial Artery Patency Study Investigators. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 2004;351: 2302-2309.
Gaudino M, Tondi P, Benedetto U, Milazzo V, Flore R, Glieca F, et al. Radial artery as a coronary artery bypass conduit: 20-year results. J Am Coll Cardiol 2016;68:603-610.
Dacey LJ, Braxton JH Jr, Kramer RS, Schmoker JD, Charlesworth DC, Helm RE, et al. Northern New England Cardiovascular Disease Study Group. Long-term outcomes of endoscopic vein harvesting after coronary artery bypass grafting. Circulation 2011;123:147-153.
Sen O, Gonca S, Solakoglu S, Dalcik H, Dalcik C, Ozkara A. Comparison of conventional and no-touch techniques in harvesting saphenous vein for coronary artery bypass grafting in view of endothelial damage. Heart Surg Forum 2013;16:E177-E183.
Kim YH, Oh HC, Choi JW, Hwang HY, Kim KB. No-touch saphenous vein harvesting may improve further the patency of saphenous vein composite grafts: Early outcomes and 1-year angiographic results. Ann Thorac Surg 2017;103:1489-1497.
Benedetto U, Lau C, Caputo M, Kim L, Feldman DN, Ohmes LB, et al. Comparison of outcomes for off-pump versus on-pump coronary artery bypass grafting in low-volume and high-volume centers and by lowvolume and high-volume surgeons. Am J Cardiol 2018;121:552-557.
Lapar DJ, Mery CM, Kozower BD, Kern JA, Kron IL, Stukenborg GJ, et al. The effect of surgeon volume on mortality for off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 2012;143:854-863.
Afilalo J, Rasti M, Ohayon SM, Shimony A, Eisenberg MJ. Off-pump vs on-pump coronary artery bypass surgery: An updated meta-analysis and meta-regression of randomized trials. Eur Heart J 2012;33: 1257-1267.
Lemma MG, Coscioni E, Tritto FP, Centofanti P, Fondacone C, Salica A, et al. On-pump versus off-pump coronary artery bypass surgery in high-risk patients: Operative results of a prospective randomized trial (on-off study). J Thorac Cardiovasc Surg 2012;143:625-631.
Rosenblum JM, Harskamp RE, Hoedemaker N, Walker P, Liberman HA, de Winter RJ, et al. Hybrid coronary revascularization versus coronary artery bypass surgery with bilateral or single internal mammary artery grafts. J Thorac Cardiovasc Surg 2016;151:1081-1099.
Harskamp RE, Brennan JM, Xian Y, Halkos ME, Puskas JD, Thourani VH, et al. Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: An analysis from the society of thoracic surgeons adult cardiac database. Circulation 2014;130: 872-879.
Puskas JD, Halkos ME, DeRose JJ, Bagiella E, Miller MA, Overbey J, et al. Hybrid coronary revascularization for the treatment of multivessel coronary artery disease: A multicenter observational study. J Am Coll Cardiol 2016;68:356-365.
Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003;138: 7777-7786.
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-1722.
Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 2014;35:1949-1956.
Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103: 2816-2821.
Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41: Ô 1283-1288.
Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- A nd paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: A prospective cohort study. Circulation 2012;125:1110-1121.
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-1674.
Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-146.
Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, et al. Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V Investigators. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): A randomised non-inferiority trial. Lancet 2013;381: 661-669.
Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, et al. Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISARTEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009;30:2441-2449.
Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): A randomised, controlled, non-inferiority trial. Lancet 2013;381:651-660.
Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- A nd Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators. Polymer-free sirolimus- A nd probucoleluting versus new generation zotarolimus-eluting stents in coronary artery disease: The Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- A nd Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 2011;124:624-632.
Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: Executive summary. Eur Heart J 2015;36: 2608-2620.
Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, et al. NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 2016;375:1242-1252.
Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and baremetal stents: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2015;65:2496-2507.
Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D, et al. SENIOR Investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): A randomised single-blind trial. Lancet 2018;391: 41-50.
Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, et al. Biodegradable-polymer drug-eluting stents vs bare metal stents vs durable-polymer drug-eluting stents: A systematic review and Bayesian approach network meta-analysis. Eur Heart J 2014;35:1147-1158.
Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-blind, non-inferiority trial. Lancet 2014;384:2111-2122.
Kaiser C, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, et al. BASKET-PROVE II Study Group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: Main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2015;131:74-81.
Raungaard B, Jensen LO, Tilsted HH, Christiansen EH, Maeng M, Terkelsen CJ, et al. Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT). Zotarolimus-eluting durablepolymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): A randomised non-inferiority trial. Lancet 2015;385:1527-1535.
von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, et al. Very thin strut biodegradable polymer everolimuseluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): A three-arm, randomised, non-inferiority trial. Lancet 2016;388:2607-2617.
Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: The EVOLVE II Randomized Trial. Circ Cardiovasc Interv 2015;8:e002372.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: A randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013;62:181-190.
Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, et al. CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: The CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J 2014;35: 2021-2031.
Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, et al. BIOFLOW Investigators V. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): A randomised trial. Lancet 2017;390:1843-1852.
Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, et al. ISAR-TEST 5 Investigators. Randomized trial of polymer-free sirolimus- A nd probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 trial. JACC Cardiovasc Interv 2016;9:784-792.
Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hoppmann P, et al. Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST 4) Investigators. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: Final results from the ISARTEST 4 randomised trial. EuroIntervention 2016;11:1372-1379.
Vlachojannis GJ, Smits PC, Hofma SH, Togni M, Vazquez N, Valdes M, et al. Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: Final 5-year report from the COMPARE II Trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent). JACC Cardiovasc Interv 2017;10: 1215-1221.
Vlachojannis GJ, Puricel S, Natsuaki M, Morimoto T, Smits PC, Kimura T. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: A pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials. EuroIntervention 2017;12:1970-1977.
Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol 2014;64: 2541-2551.
Sorrentino S, Giustino G, Mehran R, Kini AS, Sharma SK, Faggioni M, et al. Everolimus-eluting bioresorbable scaffolds versus everolimuseluting metallic stents. J Am Coll Cardiol 2017;69:3055-3066.
Montone RA, Niccoli G, De Marco F, Minelli S, D'Ascenzo F, Testa L, et al. Temporal trends in adverse events after everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent implantation: A meta-analysis of randomized controlled trials. Circulation 2017;135:ô 2145-2154.
Bondesson P, Lagerqvist B, James SK, Olivecrona GK, Venetsanos D, Harnek J. Comparison of two drug-eluting balloons: A report from the SCAAR registry. EuroIntervention 2012;8:444-449.
Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, et al. A randomized multicenter study comparing a paclitaxel drugeluting balloon with a paclitaxel-eluting stent in small coronary vessels: The BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012;60:2473-2480.
Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010;96:1291-1296.
Stella PR, Belkacemi A, Dubois C, Nathoe H, Dens J, Naber C, et al. A multicenter randomized comparison of drug-eluting balloon plus baremetal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: Six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv 2012;80:1138-1146.
Abdel-Wahab M, Richardt G, Joachim Buttner H Toelg, R Geist, V Meinertz T, et al. High-speed rotational atherectomy before paclitaxeleluting stent implantation in complex calcified coronary lesions: The randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial. JACC Cardiovasc Interv 2013;6:10-19.
Parise H, Maehara A, Stone GW, Leon MB, Mintz GS. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drugeluting stent era. Am J Cardiol 2011;107:374-382.
Lodi-Junqueira L, de Sousa MR, da Paixao LC, Kelles SM, Amaral CF, Ribeiro AL. Does intravascular ultrasound provide clinical benefits for percutaneous coronary intervention with bare-metal stent implantation A meta-analysis of randomized controlled trials. Syst Rev 2012;1: 42.
Nerlekar N, Cheshire CJ, Verma KP, Ihdayhid AR, McCormick LM, Cameron JD, et al. Intravascular ultrasound guidance improves clinical outcomes during implantation of both first- A nd second-generation drug-eluting stents: A meta-analysis. EuroIntervention 2017;12: 1632-1642.
Buccheri S, Franchina G, Romano S, Puglisi S, Venuti G, D'Arrigo P, et al. Clinical outcomes following intravascular imaging-guided versus coronary angiography-guided percutaneous coronary intervention with stent implantation: A systematic review and Bayesian network metaanalysis of 31 studies and 17882 patients. JACC Cardiovasc Interv 2017; 10:2488-2498.
Prati F, Di Vito L, Biondi-Zoccai G, Occhipinti M, La Manna A, Tamburino C, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: The Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention 2012;8:823-829.
Wijns W, Shite J, Jones MR, Lee SW, Price MJ, Fabbiocchi F, et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. Eur Heart J 2015;36:3346-3355.
Prati F, Guagliumi G, Mintz GS, Costa M, Regar E, Akasaka T, et al. Expert's OCT Review Document. Expert review document part 2: Methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J 2012;33:2513-2520.
Radu MD, Raber L, Heo J, Gogas BD, Jorgensen E, Kelbaek H, et al. Natural history of optical coherence tomography-detected non-flowlimiting edge dissections following drug-eluting stent implantation. EuroIntervention 2014;9:1085-1094.
Ali ZA, Maehara A, Genereux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, et al. ILUMIEN III: OPTIMIZE PCI Investigators. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): A randomised controlled trial. Lancet 2016;388:2618-2628.
Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: Results of the multicenter, randomized DOCTORS study (Does Optical Coherence Tomography Optimize Results of Stenting). Circulation 2016;134:906-917.
Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation 2016;133:650-660.
Souteyrand G, Amabile N, Mangin L, Chabin X, Meneveau N, Cayla G, et al. PESTO Investigators. Mechanisms of stent thrombosis analysed by optical coherence tomography: Insights from the national PESTO French registry. Eur Heart J 2016;37:1208-1216.
Kang SJ, Mintz GS, Akasaka T, Park DW, Lee JY, Kim WJ, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation 2011;123:2954-2963.
Malle C, Tada T, Steigerwald K, Ughi GJ, Schuster T, Nakano M, et al. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. Arterioscler Thromb Vasc Biol 2013;33: 1376-1383.
Gao XF, Zhang YJ, Tian NL, Wu W, Li MH, Bourantas CV, et al. Stenting strategy for coronary artery bifurcation with drug-eluting stents: A meta-analysis of nine randomised trials and systematic review. EuroIntervention 2014;10:561-569.
Behan MW, Holm NR, de Belder AJ, Cockburn J, Erglis A, Curzen NP, et al. Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Eur Heart J 2016;37:1923-1928.
Hildick-Smith D, Behan MW, Lassen JF, Chieffo A, Lefevre T, Stankovic G, et al. The EBC TWO Study (European Bifurcation Coronary TWO): A randomized comparison of provisional T-stenting versus a systematic 2 stent culotte strategy in large caliber true bifurcations. Circ Cardiovasc Interv 2016;9:e003643.
Chen SL, Zhang JJ, Han Y, Kan J, Chen L, Qiu C, et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. J Am Coll Cardiol 2017;70:2605-2617.
Erglis A, Kumsars I, Niemela M, Kervinen K, Maeng M, Lassen JF, et al. Nordic PCI Study Group. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: The Nordic stent technique study. Circ Cardiovasc Interv 2009;2:27-34.
Zheng XW, Zhao DH, Peng HY, Fan Q, Ma Q, Xu ZY, et al. Randomized comparison of the crush versus the culotte stenting for coronary artery bifurcation lesions. Chin Med J (Engl) 2016;129:505-510.
Chen SL, Xu B, Han YL, Sheiban I, Zhang JJ, Ye F, et al. Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: Results from a multicenter, randomized, prospective DKCRUSH-III study. J Am Coll Cardiol 2013;61:1482-1488.
Niemela M, Kervinen K, Erglis A, Holm NR, Maeng M, Christiansen EH, et al. Nordic-Baltic PCI Study Group. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: The Nordic-Baltic Bifurcation Study III. Circulation 2011;123: 79-86.
Gwon HC, Hahn JY, Koo BK, Song YB, Choi SH, Choi JH, et al. Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: Results from the COBIS registry. Heart 2012;98:225-231.
Genereux P, Kumsars I, Lesiak M, Kini A, Fontos G, Slagboom T, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol 2015;65:533-543.
Lassen JF, Holm NR, Banning A, Burzotta F, Lefevre T, Chieffo A, et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention 2016;12:38-46.
Henriques JP, Hoebers LP, Ramunddal T, Laanmets P, Eriksen E, Bax M, et al. EXPLORE Investigators Trial. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: The EXPLORE trial. J Am Coll Cardiol 2016;68:1622-1632.
Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 2018;39: 2484-2493.
Christakopoulos GE, Christopoulos G, Carlino M, Jeroudi OM, Roesle M, Rangan BV, et al. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions. Am J Cardiol 2015;115:1367-1375.
Brilakis ES, Banerjee S, Karmpaliotis D, Lombardi WL, Tsai TT, Shunk KA, et al. Procedural outcomes of chronic total occlusion percutaneous coronary intervention: A report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv 2015;8:245-253.
Maeremans J, Walsh S, Knaapen P, Spratt JC, Avran A, Hanratty CG, et al. The hybrid algorithm for treating chronic total occlusions in Europe: The RECHARGE registry. J Am Coll Cardiol 2016;68:1958-1970.
Galassi AR, Sianos G, Werner GS, Escaned J, Tomasello SD, Boukhris M, et al. Euro CTO Club. Retrograde recanalization of chronic total occlusions in Europe: Proceduralin-hospital, and long-term outcomes from the multicenter ERCTO registry. J Am Coll Cardiol 2015;65:2388-400.
Koh JS, Koo BK, Kim JH, Yang HM, Park KW, Kang HJ, et al. Relationship between fractional flow reserve and angiographic and intravascular ultrasound parameters in ostial lesions: Major epicardial vessel versus side branch ostial lesions. JACC Cardiovasc Interv 2012;5:409-415.
Arnous S, Shakhshir N, Wiper A, Ordoubadi FF, Williams P, Clarke B, et al. Incidence and mechanisms of longitudinal stent deformation associated with BiomatrixResolute, Element, and Xience stents: Angiographic and case-by-case review of 1, 800 PCIs. Catheter Cardiovasc Interv 2015;86:1002-1011.
Szabo S, Abramowitz B, Vaitkus P. New technique of aorto-ostial stent placement. Am J Cardiol 2005;96:212H.
Gutierrez-Chico JL, Villanueva-Benito I, Villanueva-Montoto L, Vazquez-Fernandez S, Kleinecke C, Gielen S, et al. Szabo technique versus conventional angiographic placement in bifurcations 010-001 of Medina and in aorto-ostial stenting: Angiographic and procedural results. EuroIntervention 2010;5:801-808.
Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial. Lancet 2011; 377:1409-1420.
Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, et al. European Association of Percutaneous Cardiovascular Interventions; Working Group on Acute Cardiac Care of the European Society of Cardiology; Working Group on Thrombosis on the European Society of Cardiology. Consensus document on the radial approach in percutaneous cardiovascular interventions: Position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Careand Thrombosis of the European Society of Cardiology. EuroIntervention 2013;8:1242-1251.
Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-1402.
Ferrante G, Rao SV, Juni P, Da Costa BR, Reimers B, Condorelli G, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: A meta-analysis of randomized trials. JACC Cardiovasc Interv 2016;9:1419-1434.
Sabate M, Windecker S, Iniguez A, Okkels-Jensen L, Cequier A, Brugaletta S, et al. Everolimus-eluting bioresorbable stent vs durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: Results of the randomized ABSORB STsegment elevation myocardial infarction-TROFI II trial. Eur Heart J 2016; 37:229-240.
Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimuseluting metallic stents: A meta-analysis of randomised controlled trials. Lancet 2016;387:537-544.
Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015;385:43-54.
Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, et al. Comparison of everolimus- A nd biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015;65:791-801.
Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al. ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015;36:3332-3342.
Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, et al. ABSORB China Investigators. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol 2015;66:2298-2309.
Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015;373:1905-1915.
Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, AJ IJ, et al. AIDA Investigators. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med 2017;376:2319-2328.
Cassese S, Byrne RA, Juni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, et al. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: A meta-analysis of randomised trials. EuroIntervention 2018;13:1565-1573.
Casella G, Klauss V, Ottani F, Siebert U, Sangiorgio P, Bracchetti D. Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: A meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. Catheter Cardiovasc Interv 2003;59:314-321.
Witzenbichler B, Maehara A, Weisz G, Neumann FJ, Rinaldi MJ, Metzger DC, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: The assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation 2014;129:463-470.
Maehara A, Ben-Yehuda O, Ali Z, Wijns W, Bezerra HG, Shite J, et al. Comparison of stent expansion guided by optical coherence tomography versus intravascular ultrasound: The ILUMIEN II study (observational study of optical coherence tomography [OCT] in patients undergoing fractional flow reserve[FFR] and percutaneous coronary intervention). JACC Cardiovasc Interv 2015;8:1704-1714.
Maeng M, Holm NR, Erglis A, Kumsars I, Niemela M, Kervinen K, et al. Nordic-Baltic Percutaneous Coronary Intervention Study Group. Longterm results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol 2013;62:30-34.
Hildick-Smith D, de Belder AJ, Cooter N, Curzen NP, Clayton TC, Oldroyd KG, et al. Randomized trial of simple versus complex drugeluting stenting for bifurcation lesions: The British Bifurcation Coronary Study: Old, new, and evolving strategies. Circulation 2010;121: 1235-1243.
Behan MW, Holm NR, Curzen NP, Erglis A, Stables RH, de Belder AJ, et al. Simple or complex stenting for bifurcation coronary lesions: A patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv 2011;4:57-64.
Chen SL, Santoso T, Zhang JJ, Ye F, Xu YW, Fu Q, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: Results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. J Am Coll Cardiol 2011;57:914-920.
Katritsis DG, Siontis GC, Ioannidis JP. Double versus single stenting for coronary bifurcation lesions: A meta-analysis. Circ Cardiovasc Interv 2009;2:409-415.
Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv 2011;4:952-961.
Claessen BE, Dangas GD, Godino C, Lee SW, Obunai K, Carlino M, et al. Multinational Cto Registry. Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with versus without diabetes mellitus. Am J Cardiol 2011;108:924-931.
Jones DA, Weerackody R, Rathod K, Behar J, Gallagher S, Knight CJ, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival. JACC Cardiovasc Interv 2012;5:380-388.
Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. Circ Cardiovasc Qual Outcomes 2010;3:284-290.
Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: A systematic review and meta-analysis. Am Heart J 2010; 160:179-187.
Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-697.
Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: Who, when, why, and which agent Eur Heart J 2016;37: 1284-1295.
Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
Bellemain-Appaix A, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthelemy O, et al. ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. JAMA 2012;308:2507-2516.
Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688-696.
Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3A Trial Investigators. ISARREACT 3A: A study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J 2010;31:2482-2491.
Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355: 1006-1017.
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 2013;382:1981-1992.
Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The ADVANCE Trial. J Am Coll Cardiol 2004;44: 14-19.
Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. Schomig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238.
Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: A meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol 2011;57: 1190-1199.
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377: 1319-1330.
Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro AARMYDA-5 PRELOAD Investigators. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010; 56:550-557.
Widimsky P, Motovska Z, Simek S, Kala P, Pudil R, Holm F, et al. PRAGUE-8 Trial Investigators. Clopidogrel pre-treatment in stable angina: For all patients 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI A randomized multicentre trial PRAGUE-8. Eur Heart J 2008;29: 1495-1503.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001;104:539-543.
Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590-593.
von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISARCHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950.
Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938.
Silvain J, Beygui F, Barthelemy O, Pollack C Jr, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis. BMJ 2012;344:e553.
Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012;125:2015-2026.
Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, et al. Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 vs 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36: 1252-1263.
Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: Randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv 2016;9:e003145.
Hong SJ, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, et al. IVUSInvestigators XPL. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: The IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 2016;9:1438-1446.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: The dual antiplatelet therapy randomized clinical trial. JAMA 2015;313:1113-1121.
Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-1348.
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA 2013;310:2510-2522.
Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: A pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371-2382.
Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: A systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015;65:1298-1310.
Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: Metaanalysis of randomised controlled trials. BMJ 2015;350:h1618.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-2266.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. TRITON TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-1057.
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000; 355:1936-1942.
Cohen M, Mahaffey KW, Pieper K, Pollack CV Jr, Antman EM, Hoekstra J, et al. SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-STsegment elevation acute coronary syndromes. J Am Coll Cardiol 2006; 48:1346-1354.
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: A meta-analysis of randomised controlled trials. Lancet 2014;384:599-606.
Cassese S, Byrne RA, Laugwitz KL, Schunkert H, Berger PB, Kastrati A. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: A meta-analysis of randomised trials. EuroIntervention 2015;11:196-203.
Zhang S, Gao W, Li H, Zou M, Sun S, Ba Y, et al. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Int J Cardiol 2016;209:87-95.
Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 2017;377:1132-1142.
Nührenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: A meta-analysis of randomized-controlled trials. Clin Res Cardiol 2018;107:807-815.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al. EARLY Investigators ACS. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360: 2176-2190.
Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.
Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, et al. SMART-DATE Investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): A randomised, open-label, noninferiority trial. Lancet 2018;391:1274-1284.
Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017;38:3070-3078.
Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. Lancet 2017;390:1747-1757.
Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y12 receptorinhibiting therapies. Circulation 2017;136:1955-1975.
Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115: 813-818.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011;32:2922-2932.
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. CURRENT-OASIS 7 Investigators. Double-dose versus standarddose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet 2010; 376(9748):1233-1243.
Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, et al. ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing trial. JAMA 2007;297:591-602.
Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-815.
FUTURA/OASIS-Trial Group 8, Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: The FUTURA/OASIS-8 randomized trial. JAMA 2010;304:1339-1349.
Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, et al. ; MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009.
Palmerini T, Della Riva D, Benedetto U, Reggiani LB, Feres F, Abizaid A, et al. Three, six or twelve months of dual antiplatelet therapy after drug-eluting stent implantation in patients with or without acute coronary syndromes: An individual patient data pairwise and network metaanalysis of six randomized trials and 11, 473 patients. Eur Heart J 2017; 38:1034-1043.
Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025-1034.
Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54. Eur Heart J 2016;37:1133-1142.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800.
Costa F, Adamo M, Ariotti S, Navarese EP, Biondi-Zoccai G, Valgimigli M. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect A meta-analysis. Int J Cardiol 2015;201:179-181.
Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, et al. DAPT Study Investigators. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv 2016;9:138-147.
Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J, et al. PRAGUE-18 Study Group. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: Multicenter randomized PRAGUE-18 study. Circulation 2016;134:1603-1612.
Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. ATLANTIC Investigators. Prehospital ticagrelor in STsegment elevation myocardial infarction. N Engl J Med 2014;371: 1016-1027.
Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. ATOLL Investigators. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial. Lancet 2011;378:693-703.
Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-regression analysis of randomized trials. Eur Heart J 2009;30:2705-2713.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. FINESSE Investigators. Facilitated PCI in patients with STelevation myocardial infarction. N Engl J Med 2008;358:2205-2217.
Van't Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, et al. Ongoing Tirofiban In Myocardial infarction Evaluation 2 Study Group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 2008;372: 537-546.
Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122: 2131-2141.
Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-2217.
Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230.
Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. HEATPPCI Trial Investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): An open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-1858.
Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: A nationwide study. Eur Heart J 2016;37:189-197.
Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg 2016;50:849-856.
Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016;1:921-928.
Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010;56:1994-2002.
Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti DSurgical and Clinical Outcome Research (SCORE) Group. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011;91:123-129.
Ranucci M, Colella D, Baryshnikova E, Di Dedda U; Surgical and Clinical Outcome Research (SCORE) Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 2014;113:970-976.
Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981-989.
Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. : WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107-1115.
Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619-1629.
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-2434.
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. DUAL RESteering Committee PCI and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-1524.
Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634-640.
Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, et al. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J 2018;197:133-141.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A metaanalysis of randomised trials. Lancet 2014;383:955-962.
Post PN, Kuijpers M, Ebels T, Zijlstra F. The relation between volume and outcome of coronary interventions: A systematic review and metaanalysis. Eur Heart J 2010;31:1985-1992.
Kim LK, Looser P, Feldman DN. Peri- A nd postoperative care after coronary artery bypass grafting in low versus high volume centers. J Thorac Cardiovasc Surg 2016;152:1205.
Gonzalez AA, Dimick JB, Birkmeyer JD, Ghaferi AA. Understanding the volume-outcome effect in cardiovascular surgery: The role of failure to rescue. JAMA Surg 2014;149:119-123.
Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117-2127.
Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A, Papadimos TJ, et al. Is hospital procedure volume a reliable marker of quality for coronary artery bypass surgery A comparison of risk and propensity adjusted operative and midterm outcomes. Ann Thorac Surg 2005;79:1961-199.
Kurlansky PA, Argenziano M, Dunton R, Lancey R, Nast E, Stewart A, et al. Quality, not volume, determines outcome of coronary artery bypass surgery in a university-based community hospital network. J Thorac Cardiovasc Surg 2012;143:287-293.
Auerbach AD, Hilton JF, Maselli J, Pekow PS, Rothberg MB, Lindenauer PK. Shop for quality or volume Volume, quality, and outcomes of coronary artery bypass surgery. Ann Intern Med 2009;150:696-704.
Pagano D, Kappetein AP, Sousa-Uva M, Beyersdorf F, Klautz R, Mohr F, et al. European Association for Cardio-Thoracic Surgery (EACTS) and the EACTS Quality Improvement Programme. EACTS clinical statement: Guidance for the provision of adult cardiac surgery. Eur J Cardiothorac Surg 2016;50:1006-1009.
Hannan EL, Wu C, Walford G, King SB, III, Holmes DR, Jr, Ambrose JA, et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation 2005;112:1171-1179.
McGrath PD, Wennberg DE, Dickens JD Jr, Siewers AE, Lucas FL, Malenka DJ, et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent. JAMA 2000;284:3139-3144.
Nallamothu BK, Wang Y, Magid DJ, McNamara RL, Herrin J, Bradley EH, et al. National Registry of Myocardial Infarction Investigators. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis. Circulation 2006;113:222-229.
Spaulding C, Morice MC, Lancelin B, El Haddad S, Lepage E, Bataille S, et al. CARDIO-ARIF registry Investigators. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting Results of the greater Paris area PCI registry. Eur Heart J 2006;27: 1054-1060.
Vakili BA, Kaplan R, Brown DL. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001;104:2171-2176.
Canto JG, Every NR, Magid DJ, Rogers WJ, Malmgren JA, Frederick PD, et al. The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med 2000;342:1573-1580.
Xu B, Redfors B, Yang Y, Qiao S, Wu Y, Chen J, et al. Impact of operator experience and volume on outcomes after left main coronary artery percutaneous coronary intervention. JACC Cardiovasc Interv 2016;9: 2086-2093.
Di Mario C, Di Sciascio G, Dubois-Rande JL, Michels R, Mills P. Curriculum and syllabus for Interventional Cardiology subspecialty training in Europe. EuroIntervention 2006;2:31-6.
Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol 2016;67:1-12.
Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: Secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005;143:659-72.
Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003;290:86-97.
Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-1290.
Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376: 1670-1681.
Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol 2017;70:1760-1776.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016;387: 957-967.
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-431.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: 854-865.
Harb SC, Marwick TH. Prognostic value of stress imaging after revascularization: A systematic review of stress echocardiography and stress nuclear imaging. Am Heart J 2014;167:77-85.
